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Obesity has been a worldwide epidemic for decades. Despite the abundant increase in
knowledge regarding the etiology and pathogenesis of obesity, the prevalence continues
to rise with estimates predicting considerably higher numbers by the year 2030. Obesity is
characterized by an abnormal lipid accumulation, however, the physiological
consequences of obesity are far more concerning. The development of the obesity
phenotype constitutes dramatic alterations in adipocytes, along with several other cellular
mechanisms which causes substantial increase in systemic oxidative stress mediated by
reactive oxygen species (ROS). These alterations promote a chronic state of inflammation
in the body caused by the redox imbalance. Together, the systemic oxidative stress and
chronic inflammation plays a vital role in maintaining the obese state and exacerbating
onset of cardiovascular complications, Type II diabetes mellitus, dyslipidemia, non-
alcoholic steatohepatitis, and other conditions where obesity has been linked as a
significant risk factor. Because of the apparent role of oxidative stress in the
pathogenesis of obesity, there has been a growing interest in attenuating the pro-
oxidant state in obesity. Hence, this review aims to highlight the therapeutic role of
antioxidants, agents that negate pro-oxidant state of cells, in ameliorating obesity and
associated comorbidities. More specifically, this review will explore how various
antioxidants target unique and diverse pathways to exhibit an antioxidant
defense mechanism.
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INTRODUCTION
Chronic state of obesity is an ever-growing health concern burdening millions of individuals
worldwide. Characterized physiologically as the accumulation of excess body fat, a substantial
difficulty that comes with determining treatment and prevention of the disease is the multifactorial
origin of the etiology (Hruby and Hu, 2015). The complexity of the etiology has led to obesity being
one of the most uncontrollable disease epidemics of the last four decades. Since 1980, the prevalence
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of worldwide obesity has doubled with approximately 39% of
people being overweight and 13% obese in 2014, according the
World Health Organization. Further estimations indicate that by
2030, the worldwide obesity could reach 20% (Hruby and Hu,
2015; Mohammed et al., 2018). What is more worrisome is the
increase of early onset obesity in children where obesity and
potential comorbidities persist into adulthood in approximately
50% of cases versus 10% for children without obesity (Fruh,
2017). The stark incline of prevalence across all age groups
is exceedingly concerning when considering the mortality
associated with obesity. Across all age groups, according to
compiled data of 19 cohort studies and 1.46 million
participating individuals, mortality rate generally increased
significantly in association with increased body mass index
(BMI) (Berrington de Gonzalez et al., 2010). On average,
obesity can lead to as much as a 5–10 year decrease on life
expectancy (Kuk et al., 2011; Fruh, 2017).
Obesity has been known to be a cause of wide range of
complications due to several underlying pathophysiological
processes. Comorbidities of obesity are diverse and can occur
in many bodily systems including cardiovascular complications,
type 2 diabetes mellitus (T2DM), non-alcoholic steatohepatitis
(NASH), metabolic syndrome, and several other lesser known
morbidities (Sodhi et al., 2015; Srikanthan et al., 2016; Fruh,
2017; Lakhani et al., 2018; Lauby-Secretan et al., 2019). The
trigger for obesity and associated comorbidities is intricately
linked with an increase in reactive oxygen species (ROS) and
subsequent oxidative stress. Several primary sources of
endogenous intracellular ROS have been implicated including
cellular mitochondria, endoplasmic reticulum (ER) stress,
activation of oxidative stress pathways and upregulated activity
of NADPH oxidase (NOX) (Bhatti et al., 2017). This causes a
state of redox imbalance, where the pro-oxidants are excessively
produced and the antioxidant defense mechanisms are
diminished, facilitating a state of chronic inflammation
(Fonseca-Alaniz et al., 2007; Wensveen et al., 2015). The
interlinking relation between systemic redox imbalance and
release of inflammatory mediators creates an inflammatory
milieu affecting the regulation of metabolic pathways,
consequences of which can lead to impaired physiological
functions in obesity and associated comorbidities.
Due to the modulation of redox mechanisms in obesity,
evidence suggests that a multimodal approach to treatment
including diet changes, exercise, and medical treatments may
be successful in curbing oxidant stress (Thompson et al., 2007;
Achkasov et al., 2016). One such considerable approach against
obesity is to counter the cellular pro-oxidant state by ameliorate
the excessive production of ROS and subsequent oxidative stress.
Antioxidants may present a viable therapeutic target to help
ameliorate the negative effects of obesity and oxidative stress on
the physiological systems of the body. The cumulative line of
evidence suggests that antioxidants may modulate dynamic
cellular targets and processes to improve the redox imbalance
in obesity. The mechanisms involved in the regulation of cellular
redox present increasing importance of unraveling the potential
of endogenous and exogenous antioxidants in ameliorating
obesity associated phenotype. Hence, this review aims to
independently uncover the potential of several antioxidants in
ameliorating obesity phenotype and associated comorbidities.
Specifically, this review presents evidence from past literature in
elucidating the role of antioxidants in improving antioxidant
defense mechanism by manipulating localized redox signaling
pathways in an obese state.
OXIDATIVE STRESS IN OBESITY AND
ASSOCIATED COMORBIDITIES
The complex relationship between obesity and the associated
comorbidities involves, first, the dysregulation of the vital
communication system that adipocytes have within the body.
Compared to the smaller, healthy adipocytes, the influence of
obesity is drastic causing a transition to a subset of large,
dysfunctional adipocytes (Lakhani et al., 2018). These larger
adipocytes suffer from poor regulation mechanisms that
disrupt the normal signaling functions that adipocytes play
(Haczeyni et al., 2018). There are over 50 known adipokines
that are released as signaling molecules from adipocytes
including leptin, adiponectin, multiple interleukins, and TNF-a
to name a few (Stolarczyk, 2017). In the obese model, the balance
of these signaling adipokines are significantly disrupted. Pro-
inflammatory adipokines (IL-6, TNF-a, MCP-1) and leptin,
associated with the maintenance of the obese state, are elevated
during the obese state whereas adiponectin, which plays an
important role in insulin sensitivity, is decreased, connecting
its role to insulin resistance and T2DM (Friedman and Halaas,
1998; Sirico et al., 2018). The increased levels of these pro-
inflammatory adipokines place the body into a perpetual state of
inflammation, or chronic inflammation. During the onset of
obesity, this added inflammatory burden and subsequent
adipocyte turnover/remodel to account for the increased fat
accumulation is destructive to the cellular environment.
Macrophages, which are recruited to aid in the adipocyte
turnover, have also been implicated with obesity to potentiate
the subsequent negative effects (Kuroda and Sakaue, 2017).
Following the stark transition to the state of chronic
inflammation, the physiological environment quickly becomes
burdened with oxidative stress in the form of increased ROS and
oxidative radicals. One particular cellular component of concern
following initial increase in ROS is at the mitochondrial level.
Mitochondria, when functioning healthily, is already well-known
as a major generator of ROS in the body (Oyewole and Birch-
Machin, 2015). Invasion of macrophages to remodeling adipose
tissue breaks down older adipocytes which leads to release of
lipid components, inflammatory signals, and ROS (Lee et al.,
2010). The continued release of inflammatory signals and ROS
from this cycle of apoptosis and remodeling has a harmful
effect on the mitochondria to exacerbate the inflammation and
oxidative stress (Dela Cruz and Kang, 2018). ROS plays an
imperative role in facilitating transition of healthy mitochondria
to dysfunctional mitochondria. These dysfunctional mitochondria
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and increased ROS impair the Krebs cycle and respiratory chain
(de Mello et al., 2018). The dysfunctional mitochondria produce
abnormally high amounts of ROS that create a vicious positive
feedback effect on the functional status of the mitochondria
(Wang et al., 2013; de Mello et al., 2018). Although the chronic
inflammation induces the state of oxidative stress, dysfunctional
mitochondria are vital for maintaining the diseased state.
Furthermore, brown adipose tissue (BAT) is a mitochondria
rich tissue with high oxidative capacity which have been
implicated in the process of adaptive thermogenesis (Lettieri-
Barbato, 2019). The production of mitochondrial ROS under
thermogenesis is important to maintain the bodily homeostasis,
and this process is finely controlled through feedback mechanism.
However, in a diseased metabolic condition, there is a shift in the
redox state causing more oxidative stress during thermogenesis.
This shift leads to altered expression of markers associated with
thermogenesis causing an alteration in the adipocyte phenotype
(Lettieri-Barbato, 2019). Studies have demonstrated a causal
relationship between mitochondrial ROS and thermogenesis
using the mitochondria-targeted antioxidant MitoQ, which
efficiently ameliorates lipid peroxides and superoxides in vivo
(Rodriguez-Cuenca et al., 2010). It is important to note that the
redox changes occurring in BAT upon thermogenesis are
dynamic, reversible and adapted to by antioxidant pathways
(Chouchani et al., 2017).
This perpetual state of oxidative stress and inflammation is what
links obesity to its associated comorbidities. The detrimental role
that this diseased state plays on the cardiovascular system is
substantial. Chronic inflammation has a negative effect on
cardiovascular tissue contributing to the associated cardiovascular
disease (CVD) and arteriosclerosis (Libby, 2006). With respect to
obesity, the chronic, low-grade inflammation and oxidative from
obesity places the cardiovascular system at an increased risk for
developing plaques in blood vessels and cardiac remodeling (Kachur
et al., 2017). Two studies, one done clinically with patients and the
other inmice on high-fat diet, have shown that increased pressure in
the heart stimulated an increase in function of NADPH oxidase 4
(NOX4), primarily located in the mitochondria of cardiac myocytes
(Kuroda et al., 2010; Munzel et al., 2017). Under states of stress,
NOX4 produces superoxide (O2
−) to exacerbate the oxidative stress
of the cardiovascular system (Kuroda et al., 2010). The
inflammatory signals released by adipocytes also contribute to
altering the physiology of the heart in obesity. Adiponectin,
downregulated in obesity, plays a protective role in the heart by
stimulating endothelial nitric oxide synthase (eNOS) to maintain
healthy vascular tone. Conversely, the rising leptin levels in the heart
positively correlate with coronary artery disease, left ventricular
hypertrophy, stroke, and myocardial infarction (Soderberg et al.,
1999;Wallace et al., 2001; Chait and den Hartigh, 2020). Along with
pro-inflammatory circulating signals, a transcription factor, NF-kB,
is a product of chronic inflammation in cardiovascular tissue and is
a useful clinical indicator for obesity-related inflammation (de
Almeida et al., 2020).
Insulin resistance and T2DM are also example of diseases
extensively linked as a comorbidity of obesity. A few of the
prominent inflammatory adipokines associated with decreasing
insulin sensitivity in tissues are IL-6 and TNF-a (Stolarczyk,
2017). In addition, IL-10 and adiponectin, two adipokines that
promote insulin sensitivity are decreased in the obese state
(Stolarczyk, 2017). Meanwhile, oxidative stress promotes a
diabetic state by disrupting certain metabolic pathways such as
inhibiting G-3-P dehydrogenase, stimulating buildup of G-3-P,
and up-regulating glycolytic, hexosamine, advanced glycation
end-product (AGE), protein kinase C, and polyl pathways
(Ighodaro, 2018). Despite the specific mechanisms not being
completely understood, the primary method by which obesity
links to T2DM is through insulin resistance (Burhans et al.,
2018). One proposed mechanism observed over multiple studies
(but not all) is that as adipogenesis takes place, the adipocytes
become dysregulated and release a larger amount of free fatty
acids (FFA) into circulation (Mittendorfer et al., 2009). The FFA-
mediated insulin resistance involves the products of oxidation of
FFA in tissues which exacerbates already impaired glucose
metabolism (Randle et al., 1965). Several in vitro studies have
revealed a secondary mechanism linking the adipokine, TNF-a,
to insulin resistance by regulating ceramide synthesis (Grigsby
and Dobrowsky, 2001; Hernandez-Corbacho et al., 2015).
Oxidative stress and inflammation resulting from obesity is a
systemic problem impacting several regions of the body through






Peroxiredoxins (Prxs) are a family of peroxidase enzymes that
have a highly conserved function to reduce hazardous peroxides
in the body. There are a few different subtypes within the Prx
family, but the mechanism of action of the class as a whole is
mediated through a highly conserved peroxidatic cysteine
residue (CP) (Hall et al., 2009). Despite the fact that the
catalytic function of all Prxs is conserved involving oxidation
of the CP by the peroxide substrate to sulfenic acid, the recycling
of the sulfenic acid back to thiol is the defining feature of the
three classes of Prxs: typical 2-Cys, atypical 2-Cys, and 1-Cys
Prxs (Wood et al., 2003; Rhee, 2016). In the mammalian system,
there are six known peroxiredoxin subtypes including PrxI-IV
(typical 2-Cys), PrxV (atypical 2-Cys), and PrxVI (1-Cys)
(Perkins et al., 2015).
Prxs are widespread across the body, and the subtypes are
localized to several different cellular compartments to play a
universal role against oxidative stress. PrxI and PrxII are both
found predominantly in the cytosol or nuclei of cells with PrxII
playing a vital role in protecting erythrocytes (Rhee et al., 2012).
PrxIII (typical 2-Cys) and PrxV (atypical 2-Cys) are both found
in the mitochondria where they are the primary antioxidant
defense mechanism against the most abundant producer of ROS.
PrxV, however, has also been found in peroxisomes and cytosol
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(Perkins et al., 2015). PrxIV is the only subtype to be identified in
the endoplasmic reticulum, which is vital for its antioxidant role
governing protein processing protection (Rhee et al., 2012;
Yamada and Guo, 2018). The only 1-Cys structural subtype is
PrxVI, and this enzyme resides in the cytosolic and lysosomal
compartments in cells (Fisher, 2018).
Because of the highly conserved antioxidant function in
reducing peroxide agents, the extensive bodily coverage of
Prxs allows them to play a significant role in obesity-induced
oxidative stress and complications. In mice with PrxV knockout
on high-fat diet, progression to obesity and enhanced
adipogenesis was far more likely than mice without the gene
knockout. Mice with PrxV treatment saw decreased levels of
PPARg and C/EBPa, two markers that indicate an adipogenic
state (Kim et al., 2018; Hammarstedt et al., 2018). Another study
induced hepatic steatosis in a HepG2 cell line with treatment of
FFA to simulate an obese state in vitro. Inducing PrxV
overexpression ameliorated hepatic steatosis progression by
inhibiting lipogenesis associated protein, SREBP-1 and RAS,
and FFA-induced mitochondrial ROS generation (Kim et al.,
2020). A follow-up study in mice revealed that the mechanism
of PrxV in achieving this role appears to be through
phosphorylation of AMPK pathway (Kim et al., 2020). Two
separate studies have also implicated PrxIV and PrxVI in having
a protective role against steatosis by targeting mitochondrial
ROS generation (Yamada and Guo, 2018; Lee et al., 2019).
Another study found that PrxIII was expressed at high levels
in 3T3-L1 mature adipocytes (Huh et al., 2012). Subsequently,
PrxIII knockout (KO) in mice produced a substantial increase in
adipocyte hypertrophy and fat mass compared to wild-type mice.
The PrxIII KO mice were observed to have increased levels
of mitochondrial ROS generation, adipogenic markers,
aP2, CCAAT/enhancer binding proteins (C/EBPa), and
peroxisomal proliferator activated receptor g (PPARg), and
protein carbonylation. The study also demonstrated decreased
levels of adiponectin, alteration of mitochondrial biogenesis, and
other antioxidant enzymes in mitochondria. The PrxIII KO mice
were identified to have impaired glucose metabolism and insulin
resistance (Huh et al., 2012). Although the mechanism to how
PrxIII regulates adipocyte function has yet to be established, this
study provides ample data to strongly suggest therapeutic
implications for PrxIII in obesity.
Similarly, recent study also identified PrxVI as a vital
component leading to an early stage of T2DM with diabetic
dyslipidemia in PrxVI KO mice (Pacifici et al., 2014). In the KO
mice, elevated levels of triglycerides and VLDLs were identified; a
hallmark indicator of adipocyte dysregulation in obesity
(Makhoul et al., 2011). Similarly, the PrxVI KO mice exhibited
increased levels of pro-inflammatory cytokines, TNFa, IL-1b, IL-
10, and IL-6, from adipose tissue. Altogether, this study
exemplifies PrxVI in protecting against progression to T2DM
with diabetic dyslipidemia (Pacifici et al., 2014). PrxIV is another
subtype implicated in its protective role against diabetes due to
stimulation of enhanced insulin secretion (Mehmeti et al., 2014).
Overall, the mechanisms responsible for mediating the
antioxidant actions of Prxs against obesity are somewhat
undiscovered or undefined due to the relative recency of many
studies involving Prx. However, there is growing evidence
linking some Prx subtypes as key protective mechanisms
against obesity-induced inflammation and comorbidities.
N-Acetylcysteine (NAC)
N-Acetylcysteine (NAC) is an antioxidant that serves to reduce
ROS through both direct and indirect effects (Mokhtari et al.,
FIGURE 1 | Schematic representation demonstrating impact of oxidative stress in obesity. Obesity mediates excessive production of ROS which leads to chronic
inflammation and altered adipocyte phenotype which further induces several systemic changes causing oxidative stress. Such oxidative stress leads to the
development and progression of chronic diseases such as T2DM, cardiovascular diseases and/or NASH.
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2017). The direct effects revolve around its’ ability to react with
hydroxyls, nitrogen dioxide and carbonate (Samuni et al., 2013).
The indirect effects arise from NAC being derived from a
conditionally essential amino acid, L-cysteine and subsequently
provides the cysteine for the formation of glutathione, a well-
established potent physiological antioxidant (Kerksick and
Willoughby, 2005). However, the oral bioavailability of
glutathione is controversial (Allen and Bradley, 2011; Richie
et al., 2015). Therefore, NAC is marketed as an over-the-counter
oral antioxidant supplement while being utilized in many
treatment protocols and clinical studies with relatively low
adverse effects (Schmitt et al., 2015).
The role of NAC in obesity has yielded promising results
across countless studies. Given that obesity is characterized by
elevated levels of oxidative stress and inflammation has made
NAC a profound target for research to minimize the progression
of obesity and associated co-morbidities (Manna and Jain, 2015;
McMurray et al., 2016). Recent in vitro studies have been able to
demonstrate a beneficial role in attenuating biomarkers
associated with adipocyte differentiation pathways such as
PPARg and C/EBPb in 3T3-L1 preadipocyte cells (Calzadilla
et al., 2011). The reduction in these biomarkers was shown
to be equal to glutathione level elevation through NAC
supplementation, reducing ROS, that upregulate the activity of
PPARg and C/EBPb (Lee et al., 2009; Calzadilla et al., 2011; Pratt
et al., 2019). This allows for speculation that supplementation of
NAC during the progression of obesity could reduce
adipogenesis through elevation of glutathione level content.
Furthermore, in vivo studies revealed that supplementation of
NAC in murine models that were fed a high fat diet to induce
obesity, reduced triglyceride and cholesterol content within the
liver by reducing PPARg levels amongst other genes involved in
hepatic storage and metabolism of lipids (Ma et al., 2016).
Studies have given promising evidence that NAC may
normalize levels of hepatic malondialdehyde and superoxide
dismutase (SOD) providing further insight that there could be
a role in preventing obesity associated co-morbidities of the liver
including NASH (Thong-Ngam et al., 2007; Korou et al., 2014).
A major factor revolving around obesity is the oxidative stress
associated inflammation present across various metabolic tissues
that has shown to be linked to insulin resistance, atherosclerosis,
and ischemic strokes (Manna and Jain, 2015; Assari and
Bazargan, 2019). The plausible efficacy of NAC in
counteracting obesity associated inflammation and apoptosis
that contributes to progression of metabolic disorders is
attributed to NAC’s ability to reduce inflammatory cytokines
and apoptotic factors while increasing antioxidant components
(Samuni et al., 2013; de Andrade et al., 2015). These anti-
apoptotic effects are elicited by the increased levels of SOD,
catalase, glutathione peroxidase and activity of peroxynitrate
which serve to reduce ROS (Zaragoza et al., 2000; de Andrade
et al., 2015). In vitro studies uncovered further contributions to
the reduction of inflammation and apoptosis by NAC reducing
levels of vascular cell adhesion molecule 1 (VCAM-1), TNF-a,
IL-6, IL-8, Ikb kinase and subsequent activation of NF-kB, which
have roles in multiple inflammatory cascades (Samuni et al.,
2013; de Andrade et al., 2015; Sun et al., 2019). The capability of
NAC to reduce inflammatory pathways and ROS generation may
allow for improvement in insulin sensitivity in obese individuals
that begin to progress to the development of T2DM (Fulghesu
et al., 2002; Lasram et al., 2015; Shen et al., 2018). This was
evidenced by recent studies that revealed treatment with NAC
improved plasma insulin levels, increased insulin sensitivity
across multiple tissues and increased motor activity in murine
models of obesity (Lasram et al., 2015; Shen et al., 2018). The
increase in motor activity could be attributed to NAC’s ability to
improve insulin sensitivity in skeletal muscle tissues as well as
possibly preventing the decline of skeletal muscle sodium
potassium adenosine triphosphatase (Na+/K+ ATPase) activity
allowing for slowed muscle fatigue (McKenna et al., 2006). Both
of these contributions could indicate a theoretical route of
research to determine if any correlation exists between NAC
and increased total daily energy expenditure in obese individuals
which may be combined with proper diet, decreasing the total
degree of inflammation by reducing adiposity and fat mass.
Furthermore, NAC was shown to improve insulin sensitivity
and glucose utilization in hyperglycemia induced mice via high
sucrose diet as well as in human volunteers during a
hyperglycemic clamp (Ammon et al., 1992; Diniz et al., 2006).
These studies reinforce the plausible link between NAC and
improving insulin sensitivity to glucose which may provide
insight into improvement of glucose utilization within obese
individuals that have progressed to developing T2DM (Straub
et al., 2019).
The current cumulative line of evidence strongly suggests that
NACmay have a role in being utilized as a cardioprotective agent
by reducing hyperglycemia induced oxidative damage to cardiac
myocytes and cardiac remodeling (Chen et al., 1985; Dludla et al.,
2017). This reduction in oxidative stress attenuates a progressive
loss in cardiac efficiency and cardiac fibrosis that would have
progressed to more severe clinical outcomes prior to intervention
(Seddon et al., 2007; Talasaz et al., 2013). Data from multiple
studies indicated that NAC elevated levels of SOD and
glutathione in cardiac myocytes, while reducing levels of TGF-
b, lipid hydroperoxides and various biomarkers for oxidative
stress (Haleagrahara et al., 2011; Talasaz et al., 2013; Dludla et al.,
2017). Obesity and T2DM both exhibit a characteristic feature of
hypercoagulable states through chronic inflammation associated
with obesity and dysregulation of platelet aggregation (Anderson
and Weitz, 2010; Blokhin and Lentz, 2013; Widjaja et al., 2019).
Studies have uncovered that NAC may have a potential role in
reducing the likelihood of thrombus generation through
elevation of platelet glutathione levels and nitric oxide
(Girouard et al., 2003; Martinez de Lizarrondo et al., 2017;
Craver et al., 2020). The elevation in platelet glutathione
ameliorated platelet ROS preventing oxidative constituents to
induce coagulation cascades (Wang et al., 2016). It was also
indicated that NAC may exert antagonistic effects toward Von
Willebrand factor, a necessary component of coagulation
cascades, reducing the risk of thrombosis and stroke (Wang
et al., 2016; Martinez de Lizarrondo et al., 2017). Through
elevating levels of nitric oxide, NAC may have a possible role
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in regulation of high blood pressure in obese individuals via
nitric oxide mediated vasodilation (Zicha et al., 2006; Gibson
et al., 2011). NAC’s cardioprotective abilities also correlate to its
ability to reduce the expression of malic enzyme, fatty acid
synthase and other enzymes involved in biosynthesis of
triglyceride and cholesterol biosynthesis pathways (Lin and
Yin, 2008; Korou et al., 2010; Korou et al., 2014; Ma et al.,
2016). This cardioprotective ability may indicate that NAC may
play a role in prevention of atherosclerosis.
Vitamin E
Vitamin E (VitE) primarily describes a group of eight compounds
known as tocopherols and tocotrienols where each group consists of
a, b, g, and d tocopherol/tocotrienol compounds (Colombo and
vitamin, 2010; Rizvi et al., 2014). Each of the eight compounds, has
shown to elicit some degree of antioxidant properties. However, of
all the compounds the constituent a-tocopherol (aT) possesses the
highest physiological concentrations (Baxter et al., 2012). It has been
shown extensively that aT acts as an antioxidant through its
chromanol ring, allowing it to scavenge and remove ROS
preventing oxidative damage (Ahsan et al., 2015). Through their
lipophilic characteristics, aT serves to protect polyunsaturated fatty
acids present in membrane phospholipids and lipoproteins to
stabilize cellular membranes (Kuznetsov et al., 1993; Wallert et al.,
2014; Galmes et al., 2018). Many studies have suggested a positive
correlation between aT and attenuating inflammation, clinical
disorders and promoting immune system functionality (Galmes
et al., 2018; Lewis et al., 2019). This research along with VitE being
widely available, obtained solely from the diet particularly from
vegetable oils, has peaked interest into incorporating aT
supplementation into many treatment protocols of various clinical
disorders including metabolic syndrome where individuals are
shown to have lower levels of aT (Montonen et al., 2004;
Mehmetoglu et al., 2011). This may indicate that the development
and progression of obesity related metabolic syndrome could in
part be attributed to reduced levels of aT (Lira et al., 2011).
Recent in vivo studies in models of obesity and human studies
have indicated that aT supplementation was capable of attenuating
inflammatory processes by reducing the expression of IL-6, TNF-a,
malondialdehyde and C reactive protein while increasing
antioxidant constituents (Patrick and Uzick, 2001; Wong et al.,
2017). Furthermore, aT may also act to inhibit pathways that are
activated by ROS such as p38MAPK (Schett et al., 2008; Thalhamer
et al., 2008; Wang et al., 2011; Wong et al., 2017). These pathways
tend to be elevated in obese individuals, various inflammatory
pathologies and are diminished with aT supplementation (Wong
et al., 2017; Donohoe et al., 2020). Administration of aT in obese
individual induces differentiation of macrophages toward an M2
phenotype that exhibits anti-inflammatory effects (Alcala et al.,
2015; Ray et al., 2016). Thus, aT may have a plausible role in
reducing inflammation mediated by ROS-induced oxidative
damage and exert effects on immune system functionality (Lee
and Han, 2018).
The ability of aT to reduce total cholesterol and triglycerides has
yielded promising results in metabolic syndrome patients and in
prevention of obesity associated atherosclerosis (Upston et al., 2003;
Wong et al., 2017). These beneficial effects elicited by aT are
mediated through the reduction of low density lipoprotein (LDL),
high density lipoprotein (HDL) and total cholesterol levels (Upston
et al., 2003; Kirmizis and Chatzidimitriou, 2009; Wong et al., 2017).
In murinemodels of diet induced obesity, aT diminished the degree
of hepatic steatosis and circulating triglycerides indicating a
plausible role in the prevention of atherosclerosis and NASH,
associated with obesity (Kawanaka et al., 2013; Alcala et al., 2015).
Cumulative evidence across diabetic individuals, and various animal
models indicate that aT is able to reduce lipid peroxidation within
cellular membranes and reduce overall lipid content in circulation
(Kuznetsov et al., 1993; Wiseman et al., 1995; Eder et al., 2004). This
same reduction of lipids can also be seen within adipocytes as aT
may serve a role in shifting themetabolic profile of obese individuals
toward normalcy. These deviations within adipocytes in obese
individuals compared to non-obese individuals includes an
elevation of matrix metalloproteinase activity and collagen
deposition (Sun et al., 2013; Lauhio et al., 2016). The
accumulation of collagen prevents adipocyte expansion and may
contribute to the phenotype and inflammation seen in obesity (Unal
et al., 2010; Jaoude and Koh, 2016; Lin et al., 2016; Wong et al.,
2017). However, supplementation with aT promoted adipocyte
differentiation and expansion indicating that aT may play a role in
downregulating pathways associated with collagen accumulation
and abnormal adipocyte growth to attenuate the pathogenic obesity
phenotype (Kim et al., 2007).
Cumulative studies have indicated that aT supplementation
reduces biomarkers of lipid peroxidation in T2DM patients and
improve insulin sensitivity (Wu et al., 2007; Thalhamer et al.,
2008; Murer et al., 2014; Niki, 2015). The elevation in insulin
sensitivity may be attributed to the anti-inflammatory action of
aT in visceral adipose tissue, by reducing the level of p38
phosphorylation, which is associated with many inflammatory
responses and insulin resistance (Wu et al., 2007; Wong et al.,
2017). Through scavenging of ROS, aT may serve to ameliorate
the impact that persistent hyperglycemic conditions have on
promoting ROS production and inflammatory cascade activation
(Alcala et al., 2015; Wong et al., 2017). Thus, there may be a role
linking aT’s effects on inflammatory cascades that may lead to
the attenuation of the diabetic phenotype (Lee et al., 1999).
The actions of aT have shown to attenuate production of
ROS and activity of protein kinase C (PKC) pathways associated
with cellular cascades that promote proliferation and
differentiation (Martin-Nizard et al., 1998). These cascades
have shown to be affected by aT through increasing the
expression of biological compounds that inhibit PKC resulting
in the downregulation of a multitude of cascades (Engin, 2009).
Among these cascades, aT exhibits an inhibitory effect on the
proliferation of vascular smooth muscle cells that may contribute
to CVD diseases such as atherosclerosis (Nakashima et al., 1998),
indicating that aT may have a plausible role in cardio protection
(Engin, 2009; Rizvi et al., 2014). Evidence has highlighted that aT
serves a role in cardioprotective mechanisms through prevention
of retinal vascular disease in hyperglycemic states associated with
T2DM patients by inhibition of these PKC mediated pathways
(Engin, 2009). aT may also serve to attenuate platelet
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aggregation, stimulate prostacyclin release, and elevate nitric
oxide synthase (Rizvi et al., 2014). Moreover, aT reduced the
systolic blood pressure through increasing nitric oxide synthase
activity in murine models of hypertension (Tran and Chan, 1990;
Rizvi et al., 2014). Thus, the elevation of prostacyclin and
nitric oxide synthase uncovers a plausible cardioprotective
mechanism against hypertension as both are potent
vasodilators (Moncada and Vane, 1979; Ahmad et al., 2018).
Evidence accumulated across in vitro studies suggest that aT
may lower the levels of TNF-a induced stimulation of
intracellular cell adhesion molecule (ICAM-1) and VCAM-1
(Kirmizis and Chatzidimitriou, 2009; Cook-Mills et al., 2013;
Cook-Mills, 2013; Rizvi et al., 2014). This downregulation may
indicate diminished platelet aggregation and plausible reduction
in the risk for atherosclerosis and thrombosis (Nakashima et al.,
1998; Rizvi et al., 2014).
Heme Oxygenase-1
Heme oxygenase-1 (HO-1) has been established as a stress-
inducible enzyme that possesses cytoprotective, anti-
inflammatory and antioxidant properties (Nath, 2006; Araujo
et al., 2012). Other functions include its role in the rate limiting
step for heme degradation as it exerts an indirect antioxidant
effect in this manner through the degradation products (Nath,
2006). Heme is a potent pro-oxidant that serves to increase
production of ROS seen in many pathological states (Wu et al.,
2019). HO-1 degrades heme through a series of catabolic steps
that yield products including biliverdin, carbon monoxide (CO)
and free iron (Gozzelino et al., 2010). These effects have sparked
interest into multitudes of studies for incorporation into
therapeutic regimens for a plausible impediment of disease
progression in various inflammatory diseases, CVD and
metabolic dysregulation associated with obesity (Durante,
2003; Pae and Chung, 2009; Bereczki et al., 2018).
The importance of functioning HO-1 has been shown by in
vivo HMOX1 gene KO murine models (Poss and Tonegawa,
1997; Chan et al., 2011; Ayer et al., 2016). Studies have shown
that induced deficiency of HO-1 results in chronic inflammatory
states with elevated levels of pro-inflammatory cytokines that are
similar to the levels in various inflammatory diseases (Poss and
Tonegawa, 1997; Chan et al., 2011; Lenoir et al., 2017). The anti-
inflammatory effects elicited by HO-1 under normal conditions
can be attributed to its ability to degrade free heme. In excess,
free heme has the capability to contribute to the pathology of
various inflammatory diseases through destabilizing cellular
membranes, damaging organelles and DNA (Kumar and
Bandyopadhyay, 2005; Sparkenbaugh et al., 2015). Biliverdin,
CO and free iron produced from degradation of heme have been
shown to elicit anti-inflammatory actions through a variety of
different cascades (Peterson et al., 2020). CO is able to reduce
pro-inflammatory cytokines attributing to the toxicity of free
heme including TNF-a, IL-1b and IL-2 through its actions on
MAPK and NF-kb pathways (Kruger et al., 2006; Wang et al.,
2009; Burgess et al., 2010; Paine et al., 2010; Chan et al., 2011).
This reduction in IL-2 may contribute to most of the anti-
proliferative actions associated with CO signaling (Pae et al.,
2004; Pae and Chung, 2009). Biliverdin may also regulate its anti-
inflammatory actions through multiple mechanisms that involve
the inhibition of NF-kb and enhancing production of anti-
inflammatory constituents (Pae and Chung, 2009). The free
iron that is released from heme degradation possess
inflammatory and cytotoxic characteristics (Dutra and Bozza,
2014). However, to compensate for the elevation in free iron
from heme degradation, HO-1 upregulates ferritin synthesis that
is capable of storing free iron preventing possible initiation of
otherwise harmful inflammatory cascades (Balla et al., 1992; Pae
and Chung, 2009). Through the suppression of pro-
inflammatory mediators and antioxidant actions, HO-1 and
the products of heme degradation are able to reduce
inflammation and possibly diminish the phenotypic expression
associated with obesity.
Through the reduction in proinflammatory mediators
directly and indirectly, HO-1 may contribute to improving
insulin sensitivity in diabetics, reducing adipogenesis and the
probability of CVD development. Recent studies indicate that the
reduced adipogenesis and adipocyte dysfunction may be
attributed to the regulation of HO-1 mediated Wnt/b-catenin
pathways that act to reduce expression of PPARg and C/EBPa
(Siersbaek et al., 2010; Cao et al., 2012; Khitan et al., 2014).
Biliverdin, produced via HO-1 degradation of heme, may
contribute to normalizing adipocyte function by exerting
regulatory effects on PKC pathways (Wegiel and Otterbein,
2012; Khitan et al., 2014). By limiting adipogenesis, adipocyte
proliferation and differentiation, HO-1 is able to reduce the
inflammatory response within adipocytes promoting a more
stable microenvironment (Cao et al., 2012; Wagner et al.,
2017). This is due to smaller adipocytes being more responsive
to insulin and release higher concentrations of adiponectin
compared to larger adipocytes (Peterson et al., 2019). The
improvement of insulin action can be attributed to the effects
of HO-1 attenuating the expression of insulin resistance
mediators including TNF-a, IL-1b and increasing the levels of
adiponectin (Kim et al., 2008; Burgess et al., 2010; Cao et al.,
2012). Adiponectin is a hormone that is released from
adipocytes, that possesses anti-inflammatory characteristics
and confers insulin sensitivity (Li et al., 2008). The actions of
adiponectin resemble those of HO-1, that decreases the
expression of TNF-a, IL-1b, NF-kb signaling as well as other
inflammatory mediators to subvert this pathological phenotype
(Kim et al., 2008; Burgess et al., 2010; Aprahamian and Sam,
2011). Furthermore, adiponectin and HO-1 both serve to act on
inhibiting AMPK pathway, which is profound in obesity
associated inflammation (Hosick and Stec, 2012; Sodhi et al.,
2015; Smith et al., 2016; Achari and Jain, 2017). By inducing
adiponectin upregulation, HO-1 is able to work in concert with
adiponectin involving AMPK cascades to improve insulin
sensitivity, attenuate adipogenesis and progression of NASH
(Burgess et al., 2010; Hwang et al., 2013; Sodhi et al., 2015;
Smith et al., 2016; Peterson et al., 2019).
Further elucidating the importance of HO-1 in CVD
associated with obesity is the therapeutic use of statins that
have been shown to promote the induction of HO-1 to prevent
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atherosclerosis (Heeba et al., 2009). The ability of HO-1 to
reduce ROS and pro-oxidant constituents diminishes the risk
for oxidation of LDL providing cardioprotective mechanisms
against generation of atherosclerotic plaques (Cheng et al., 2009).
These plaques elicit higher levels of HO-1 induction that can
likely be attributed to physiological response to prevent plaque
progression, thrombus generation and activation of
inflammatory cascades in vascular endothelium (Cheng et al.,
2009; Durante, 2011). Moreover, HO-1 may attenuate vascular
inflammation by reducing VCAM levels, apoptotic factors,
release of inflammatory mediators from mast cells and
upregulating anti-apoptotic factors (Takamiya et al., 2002;
Kruger et al., 2006; Chan et al., 2011). The cardioprotective
mechanisms provided through induction of HO-1 may be
attributed to not only the direct actions of HO-1 but also the
indirect actions mediated through heme degradation products
CO and biliverdin (Chan et al., 2011; Hosick and Stec, 2012; Ayer
et al., 2016). CO may activate soluble guanylyl cyclase cascades
leading to vascular relaxation and diminishing platelet
aggregation to prevent subsequent thrombus formation
(Furchgott and Jothianandan, 1991; Cheng et al., 2009; Hosick
and Stec, 2012; Ayer et al., 2016). The actions of CO and
biliverdin also seem to mediate pathways acting on vascular
smooth muscle cell proliferation in response to injury associated
from the pathological microenvironment produced from obesity
mediated inflammatory responses (Ollinger et al., 2005; Beck
et al., 2010). Through the actions of CO and biliverdin, HO-1
inhibitory effect may attenuate the development and progression
of multiple vascular diseases associated with metabolic syndrome
and obesity (Frismantiene et al., 2018). The plausible
contribution of HO-1 in prevention of CVD, NASH, insulin
resistance, inflammation, apoptosis, oxidation and adipogenesis
provide insight into the importance of utilizing HO-1 and
associated pathways in therapeutic regimens to reduce the
morbidity and mortality associated with obesity phenotypes.
Polyphenols
Polyphenols are a type of antioxidants that are commonly found
in diets such as cranberries, red wine, green teas, and many
others (Fraga et al., 2019). Although the direct mechanism of
action of polyphenols is not well understood, many studies have
shown that polyphenols attenuates the obesity phenotype and
related comorbidities. Polyphenols has been shown to affect the
gut microbiota and stimulate signaling pathways that promote
fatty acid b-oxidation, mobilization of adipose tissue through
lipolysis, lowering of body weight and fat mass by increasing fat
use and energy expenditure through thermogenesis induction,
adipose apoptosis, satiety, and an increase in basal metabolic rate
(Castro-Barquero et al., 2018). Polyphenol’s inhibitory actions
include the downregulation of adipose differentiation and
adipogenesis, buildup of triglyceride, and chronic obesity-
related inflammation.
Cumulative lines of evidence have demonstrated the
beneficial role of polyphenol, found in cranberry extract, to
improve diet induced obese phenotype in murine model. The
study comparing a diet with high fat/high sucrose and high fat/
high sucrose with cranberry extract revealed that polyphenols
lowers total weight gain, visceral adipose tissue weight, hepatic
triglyceride accumulation, and plasma cholesterol levels (Anhe
et al., 2015). Also, mice given cranberry extract had similar
fasting glycaemia but with lower fasting insulinaemia, which
implies that polyphenols accentuate insulin sensitivity (Anhe
et al., 2015). In addition to cranberry extract, the polyphenols
present in pomegranate extracts have also been reported to
prevent and treat obesity. Previous studies have reported that
the pomegranate extract could decrease the level of lipids in the
blood with significant anti-inflammatory activities. Recent in
vitro study has also demonstrated that the polyphenols contained
in pomegranate extracts in combination with probiotics induces
synergistic effects that substantially reduces the triglyceride levels
and intracellular lipid increase (Sorrenti et al., 2019). The study
showed that in vitro treatment with pomegranate extract and
probiotics improved the expression of fatty acid synthase,
adiponectin, adipogenic markers, PPARg and SREBP, as well
as inflammatory cytokine, IL-6.
Parallel to the availability of cranberry polyphenols,
resveratrol is found in red wine and it undergoes rapid
metabolism in the small intestine and by the gut microbiota,
leading to low plasma bioavailability and complex outcomes
(Galiniak et al., 2019). Resveratrol has been shown to increase
endurance during exercise by expanding air capacity and oxygen
consumption and also increase insulin sensitivity of visceral
white adipose tissue in mice (Springer and Moco, 2019).
Consumption of resveratrol alters the composition of gut
microbiota by increasing symbiotic bacteria like Bacteroidetes
and decreasing opportunistic pathogens like Escherichia coli. The
favorable stimulation of Bacteroidetes by resveratrol decreases
the levels of trimethylamine-N-oxide (TMAO), which is
associated with chronic diseases like obesity (Schugar et al.,
2017). A fecal transplant of resveratrol-fed mice to obese mice
improved their glucose homeostasis. Another study
demonstrated that resveratrol’s protein interaction stimulates
mitochondrial biogenesis and increases the use of lipids while
decreasing glycolysis in the muscle and liver by the deacetylation
of PGC1a, leading to an increase in energy expenditure (Lagouge
et al., 2006). Concomitantly with protein interactions, resveratrol
increases lipolysis and decreases adipogenesis by the inhibition of
PPARg and SIRT1 (Houtkooper et al., 2012). Resveratrol’s
function as an antioxidant in redox cycling leads to the
activation of Nuclear factor-erythroid 2-related factor-2 (Nrf2),
increase in SOD, and reduction in BMI, blood pressure and body
weight (Springer and Moco, 2019).
Recent advances have suggested the beneficial role of
curcumin, a polyphenol antioxidant, in ameliorating obesity
phenotype. In vitro evidence suggests the ability of curcumin
in the browning of white adipocytes by increasing the protein
levels of hormone-sensitive lipase and p-acyl-CoA carboxylase,
augmenting lipolysis (Lone et al., 2016). Curcumin has been largely
implicated in attenuating insulin resistance, hyperglycemia,
hyperlipidemia and comorbidities associated with obesity
(Aggarwal, 2010). The cumulative line of evidence suggest that
curcumin can modulate various targets involved in obesity and
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metabolic diseases including, suppression of NF-kB and its
regulation inflammatory cytokines (Singh and Aggarwal, 1995),
IKK (Aggarwal et al., 2006), JNK (Wang et al., 2009). Studies in
murine models also demonstrated the effectiveness of dietary
curcumin in lowering triglycerides, cholesterol and phospholipid
levels (Rao et al., 1970; Babu and Srinivasan, 1997). Apart from
that, bergamot has also been shown to illicit antioxidant
properties and ameliorate obesity and associated comorbidities.
Bergamot is rich with flavonoids and phenolic compounds that
have been shown to improve dyslipidemia and systemic
inflammation in patients with metabolic syndrome (Musolino
et al., 2019). The mechanistic action of bergamot is mediated by
its compounds, bruteridin and melitidin, which bind the catalytic
site of HMG-CoA reductase causing inhibition of cholesterol
synthesis by replacing its endogenous substrate HMG-CoA
(Leopoldini et al., 2010). The antioxidant property of bergamot
also stimulates the growth of beneficial gut microbiota. Studies
have provided preclinical proof of concept that induction of
bergamot may improve the phenotypical and morphological
features of NASH along with reduction in adipose tissue
inflammation and inflammatory cytokines, IL-6 and TNFa,
hypoadiponectinemia, insulin resistance and dyslipidemia
(Musolino et al., 2020).
Epigallocatechin-3-gallate (EGCG) found in green tea is the
most dominantly studied catechin. Although EGCG is known for
its anti-cancer effects, studies have demonstrated a significant
role in ameliorating diabetes. In the context of T2DM, EGCG
promotes glucose homeostasis and inhibits lipogenesis and
gluconeogenesis in the liver in murine models (Li et al., 2018).
EGCG further attenuates the diabetic phenotype by improving
the wound healing process through lowering of macrophage
accumulation and inflammation (Zhang et al., 2018). When
treated with EGCG, insulin resistance along with adipose
differentiation is also lowered (Khan and Mukhtar, 2018). In
the context of lipid metabolism, EGCG stimulates b-oxidation
and lipolysis and downregulates lipogenic enzymes and lipid
emulsification (Huang et al., 2014).
Carotenoids
Carotenoids are 40-carbon molecules found in red, yellow, and
orange fruits and vegetables and are subdivided into carotenes
and xanthophylls (Langi et al., 2018). Carotenes differ in
structure from xanthophylls by the absence of oxygen groups,
while xanthophylls may have multiple oxygen groups and are
more soluble in water (Moran et al., 2018). The complexity of
their actions on lipid membranes is due to its unique action of
each carotenoid to various compositions of membranes (Johnson
et al., 2018). In the small intestine, carotenoids are emulsified
into micelles and their absorptions are facilitated by cell surface
proteins (Bohn et al., 2017). After absorption, carotenoids are
packaged into chylomicrons for transport to the liver and then
released into blood. Carotenes are usually packaged into LDL,
while xanthophylls are typically packaged into HDL (Wang et al.,
2007). Both types of carotenoids are known for their functions in
vision, but growing evidence suggests their anti-obesity activities
(Coronel et al., 2019).
FIGURE 2 | Schematic representation demonstrating the beneficial role of antioxidants in modulating obesity phenotype. Obesity mediates excessive ROS
production and inflammation which is further exacerbated by altered mitochondrial biogenesis and activation of macrophages from dysfunctional adipocytes.
The antioxidant defense mechanism scavenges ROS and ameliorates obesity phenotype.
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TABLE 1 | Summary of mechanistic action of antioxidants in ameliorating obesity phenotype and associated comorbidities.
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Studies have demonstrated the roles b-carotene play in
adipose differentiation as a vitamin A precursor. b-carotene is
cleaved by b-carotene oxygenase 1 (BCO1) into retinal and then
rapidly metabolized to transcriptionally active retinoic acid,
which is a type of vitamin A (von Lintig, 2012). In cell culture
models, retinoic acid inhibits the expression of adipogenic
transcription factors like PPARg, leading to a decrease in
adipogenesis (Schwarz et al., 1997). A rat study demonstrated
that vitamin A reduce obesity, but only when supplemented to
rats with mature adipocytes. When vitamin A was administrated
in newborns, adipocyte proliferation was promoted, while
supplementation to mature adipocyte led to loss of weight
(Coronel et al., 2019). Relatedly, a human study with 29,000
participants revealed that elevated serum b-carotene levels are
associated with lower cardiovascular and heart disease (Huang
et al., 2018). Other human studies have demonstrated that higher
b-carotene is associated with lower incidence of metabolic
syndrome (Beydoun et al., 2019) and lower body weight (Berry
et al., 2012) (PMID: 22396202). An analogous study showed that
higher serum levels of b-carotene are related to lower BMI and
subcutaneous adipose tissue in children (Canas et al., 2017).
Similar to carotenes, xanthophylls like fucoxanthin found in
seaweed elicit physiological effects against the obesity phenotype
and related diseases. Fucoxanthin is processed into fucoxanthinol in
the gastrointestinal tract and then amarouciaxanthin A in the liver
(Asai et al., 2004). The proportion of the metabolites of fucoxanthin
differ in that more fucoxanthiol is found in the visceral organs like
the lungs, heart, and kidneys, while amarouciaxanthin A is more
preferentially found in adipose white tissue (Hashimoto et al., 2009).
In vivo study with fucoxanthin and its metabolite’s actions against
the characteristics associated with obesity, demonstrated reduction
of serum and hepatic levels of triglycerides and inflammatory
cytokines like PGE2, nitric oxide, IL-1, and TNF-a (Sakai et al.,
2009; Hu et al., 2012). The study also demonstrated an increase in
HDL levels, while LDL receptor levels decreased (Beppu et al.,
2012). Furthermore, the administration of fucoxanthin led to
decrease in both mRNA expression of fatty acid synthase and
blood leptin levels (Beppu et al., 2013). Further studies have
shown that fucoxanthin upregulates uncoupling protein-1 (UCP-
1) in white adipose tissue and b3-adrenergic receptor (Adrb3),
leading to increased thermogenesis, fatty acid oxidation, energy
expenditure, and weight loss (Maeda et al., 2005). Fucoxanthinol
and amarouciaxanthin accentuates these anti-obesity actions of
fucoxanthin in later stages of adipocyte differentiation by
suppressing PPARg expression and glucose uptake (Kang
et al., 2011).
Superoxide Dismutase
Various forms of mammalian SOD are characterized by where
the enzyme is found and what metal it is catalyzed by. SOD1 and
SOD3 are associated with copper and zinc, while SOD2 requires
manganese (Zelko et al., 2002; Fukai and Ushio-Fukai, 2011).
Despite the differing compartmentalization of each forms of
SOD in the mitochondria, cytoplasm and extracellular matrix,
they all share the function of neutralizing ROS (Miao and St
Clair, 2009). Since all SODs are endogenous enzymes, SOD
murine trials are conducted through mimetics like 4-Hydroxy-
2,2,6,6-tetramethylpiperidine-N-oxyl (tempol), nanoformulated
SOD (NanoSOD), and hydrodynamic injections of SOD3
plasmids. Although SODs are known for their essential role in
handling oxidative stress, recent studies suggest a crucial role in
ameliorating the obesity phenotype.
Mimetics of SOD have been shown to attenuate the obesity
phenotype. Recent in vivo study demonstrated that mice
supplemented with tempol in their diet weighed less than
control mice (Samuni et al., 2010). In parallel, a recent study
demonstrated that in vivo treatment of NanoSOD in high fat diet
fed mice improved the levels of plasma triglyceride, liver
triglyceride, and hepatic lipid accumulation (Perriotte-Olson
et al., 2016). The anti-obesity effects of SOD were demonstrated
TABLE 1 | Continued
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This table summarizes the source of each antioxidant along with the mechanism that is modulated with the supplementation of each antioxidant. The mechanistic action of each antioxidant
results in amelioration of obesity phenotype and characteristics associated with it. The green arrow () represents upregulation and red arrow () represents downregulation of
phenotypical characteristics of obesity in response to antioxidants.
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when mice received hydrodynamic injections of SOD3 plasmids
(Cui et al., 2014). The mice induced with SOD3 showed
improvement in body weight which was similar to mice fed a
regular chow, as compared to high fat diet fed mice (Cui et al.,
2014). Concomitantly, the administration of SOD3 led to smaller
epididymal, inguinal, and perirenal white adipose tissues in
comparison to the same diet without SOD3 (Cui et al., 2014).
Furthermore, the study showed that mice fed a high fat diet with
adenoviral SOD3 vectors had lower liver weight, levels
of triglycerides, cholesterol by weight, and quantity of non-
esterified fatty acids, compared to mice fed a high fat diet (Cui
et al., 2014). The study provided a conclusive evidence that the
induction of SOD3 improved glucose tolerance and insulin
resistance in high fat diet fed mice (Cui et al., 2014).
Several studies have demonstrated that SOD analogs have
anti-obesity effects in the molecular level by influencing
metabolic pathways and related enzymes. In a cell culture of
adipocytes, tempol lowered the cellular level of PPARg and
PPARa, and this led to the downregulation of fasting-induced
adipose factor (FIAF) (Samuni et al., 2010). PPARg and PPARa
positively regulate FIAF in the liver and skeletal muscle during
the fasted state and can lead to adipogenic outcomes (Dutton and
Trayhurn, 2008). In a similar study, mice administered with
NanoSOD had markedly decreased levels of fatty acid metabolic
enzyme Carnitine Palmitoyl Transferase and a lipogenic de novo
enzyme fatty acid synthase (Perriotte-Olson et al., 2016). This
study also revealed the downregulation of the ERK1/2 signaling
pathway by NanoSOD. The ERK1/2 pathway can lead to obesity-
linked inflammation by the activation of NF-kB (Hennig et al.,
2006). In conjunction, the levels of CPT1a, CPT1b, PGC1a,
PGC1b, and UCP2, which are mRNA genes associated with
energy expenditure and lipolysis, were higher when mice were
given SOD3 (Cui et al., 2014).
Inflammation by itself or caused by excess macrophage is
intricately linked with obesity, and the induction of SODs
alleviates these outcomes. Studies have shown that mice fed a
high fat diet and administered NanoSOD, showed improvement
in obesity-related macrophage accumulation levels and
inflammatory markers like TNFa, MCP1, and MMP12 improved
(Perriotte-Olson et al., 2016). In a related study, mice that were fed a
high fat diet had crown-like signs of macrophage infiltrations, while
mice that were given a high fat diet and injected with SOD3 had
minimal signs of infiltrate (Cui et al., 2014). Activated F4/80+/
CD11c+ macrophages form these crown-like structures and leads to
the remodeling and expansion of adipose tissue (Sun et al., 2011).
The mRNA levels of obesity-related inflammation genes like F4/80,
TNFa, CD11c, MCP1 and IL6 were lower in these SOD3-
administered mice and hepatic de novo lipogenesis genes like
SREBP1c, fatty acid synthase and Scd1 were higher in mice that
were just given a high fat diet (Cui et al., 2014).
CONCLUSION
This review aims to highlight the therapeutic potential of seven
antioxidants and their mechanistic actions in ameliorating the
obese phenotype and associated comorbidities including
cardiovascular diseases, NAFLD/NASH and T2DM. We
demonstrate that obesity propagates cellular oxidative stress
and the activation of a multitude of inflammatory signaling
cascades that exacerbate the pathophysiological condition.
Obesity mediated induction of oxidative stress promotes a shift
from physiological homeostasis to favor physical profiles
associated with metabolic syndrome. This shift leads to
perturbations that include alterations within the phenotypic
expression of adipocytes, cardiovascular damage, insulin
resistance and abnormal accumulation of triglycerides playing
key roles in the morbidity and mortality associated with obesity.
Such pathological modifications promote disequilibrium within
the redox state disturbing the functionality of antioxidant
defense mechanisms. These alterations allow for the generation
and sustained action of oxidative free radicals leading to
cytotoxic, inflammatory, and apoptotic cascades to be
continually initiated. The typical non-obese phenotype allows for
scavenging of the oxidative radicals reducing the overall potential
for damage. However, the loss of this defense contributes to
developing the chronic inflammatory state associated with
obesity. Therefore, the roles of various antioxidants were
addressed for plausible therapeutic applications to improve
clinical outcomes.
The contribution of antioxidants was investigated to
determine their efficacy in attenuating the dysfunctional
phenotype. Given the ease of availability of these antioxidants
as dietary constituents and over-the-counter supplements
enables individuals to reap the benefits at minimal cost. This
offers an optimal potential therapy for the obese population to
slow the development of the obese phenotype. Not surprisingly,
the expression of these antioxidants seems to be reduced across
in vitro or in vivomodels and in obese individuals. This provides
speculation that widespread oxidative free radicals may be a
major contributor to the progression of the pathophysiology
associated with obesity and the potential need for antioxidant
supplementation in the obese population.
The actions of these antioxidants have a hallmark trait of
being able to scavenge ROS reducing oxidative stress (Figure 2).
Each individual antioxidant has its own characteristic
mechanism to counteract the pathological environment based
on their physical and chemical properties. For instance, the
lipophilicity of aT and carotenoids enable them to elicit more
beneficial effects within lipid membranes and lipoproteins
compared to others. Some of these antioxidants were able to
act through indirect and direct mechanisms allowing for the
potential to act across various pathways such as HO-1, NAC,
various polyphenols and carotenoids. Although there is a long
list of endogenous and exogenous antioxidants that have been
investigated previously to scavenge free radicals, however, the
mechanistic action of each antioxidant is distinct in terms of the
pathways they inhibit or stimulate. The specific properties of
each antioxidant, listed in this review, provides insight into
uncovering a link between which obesity induced metabolic
dysfunction they are individually able to respond to optimally,
hence these antioxidants were chosen for review. In the case of
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hypertension, it could be argued that many of the antioxidants
may serve a cardioprotective role that is equivalent to each other.
However, for hypertension and hyperglycemic conditions one
may benefit more from antioxidants that promote insulin
sensitivity and lowered blood pressure such as HO-1.
Furthermore, many of the antioxidants may serve a role
working in concert with one another promoting a synergistic
effect across multiple signaling and inflammatory cascades
that may attenuate obese phenotypes more-so than one
individual antioxidant.
Primarily, the mechanistic actions of each individual
antioxidant favored normalization within the inflammatory
responses encouraging the progression toward non-obese
phenotypes. By acting through inflammatory cascades such as
PKC and NF-kb, these antioxidants serve to reduce the levels of
various inflammatory mediators including TNF-a, IL-1 b,
VCAM-1, and IL-6 (Carlsen et al., 2009; Kirmizis and
Chatzidimitriou, 2009; Burgess et al., 2010; Rizvi et al., 2014;
Lee and Han, 2018). Furthermore, antioxidants restore the shift
in redox state during altered thermogenesis under diseased
metabolic conditions (Wood Dos Santos et al., 2018). The
antioxidants, like polyphenols and carotenoids, through
induction of thermogenesis, improves the expression of
thermogenic markers like UCP1, hence improving the overall
mitochondrial function and redox imbalance (Wood Dos Santos
et al., 2018). In addition, the activity of proliferative and
differentiative cascades within adipocytes were improved
leading to ameliorated expressions of PPARg and C/EBPa
(Schwarz et al., 1997; Calzadilla et al., 2011; Cao et al., 2012;
Khitan et al., 2014; Springer and Moco, 2019). These effects
resulted in a multitude of improvements including enhanced
insulin sensitivity, adipocyte functionality, reduced circulating
triglycerides, adipogenesis and fat mass (as summarized in Table
1). This infers that each antioxidant has the capability to
attenuate the development and progression of associated
comorbidities through their own mechanisms. Thus, indicating
that there may be a strong relationship between antioxidant
action and alleviating obesity induced oxidative damage and
metabolic dysfunction. The various roles that antioxidants
possess may provide a key to unlocking the optimal therapy
for the pathophysiology of obesity. More research is required to
determine the efficacy of antioxidants working in concert with
one another and with current pharmacotherapy in preventing/
reverting associated comorbidities of obesity.
AUTHOR CONTRIBUTIONS
Conceptualization: HL and KS. Validation: KS. Writing—
original draft preparation: ST, CS, CC, AD, SP, and HC.
Writing—review and editing: HL. Supervision: KS and JS.
Project administration: KS. Funding: JS. All authors
contributed to the article and approved the submitted version.
FUNDING
This research was supported by the BrickStreet Foundation and
the Huntington Foundation. This research was also supported by
National Institute of Health Grant R15 1R15HL150721 (to K.S.).
REFERENCES
Achari, A. E., and Jain, S. K. (2017). Adiponectin, a Therapeutic Target for
Obesity,Diabetes, and Endothelial Dysfunction. Int. J. Mol. Sci. 18 (6). doi:
10.3390/ijms18061321
Achkasov, E. E., Razina, A. O., and Runenko, S. D. (2016). Pathogenetically
targeted method for conservative treatment of obesity and overweight
correction. Klin. Med. (Mosk) 94 (7), 509–517.
Aggarwal, B. B., Shishodia, S., Sandur, S. K., Pandey, M. K., and Sethi, G. (2006).
Inflammation and cancer: how hot is thelink? Biochem. Pharmacol. 72
(11),1605–1621. doi: 10.1016/j.bcp.2006.06.029
Aggarwal, B. B. (2010). Targeting inflammation-induced obesity and metabolic
diseases by curcumin and other nutraceuticals. Annu. Rev. Nutr. 30, 173–199.
doi: 10.1146/annurev.nutr.012809.104755
Ahmad, A., Dempsey, S. K., Daneva, Z., Azam, M., Li, N., Li, P. L., et al. (2018).
Role of Nitric Oxide in the Cardiovascular and Renal Systems. Int. J. Mol. Sci.
19 (9). doi: 10.3390/ijms19092605
Ahsan, H., Ahad, A., and Siddiqui, W. A. (2015). A review of characterization of
tocotrienols from plant oils and foods. J. Chem. Biol. 8 (2), 45–59. doi: 10.1007/
s12154-014-0127-8
Alcala, M., Sanchez-Vera, I., Sevillano, J., Herrero, L., Serra, D., Ramos, M. P., et al.
(2015). Vitamin E reduces adipose tissue fibrosis, inflammation, and oxidative
stress and improves metabolic profile in obesity. Obes. (Silver Spring) 23 (8),
1598–1606. doi: 10.1002/oby.21135
Allen, J., and Bradley, R. D. (2011). Effects of oral glutathione supplementation on
systemic oxidative stress biomarkers in human volunteers. J. Altern.
Complement Med. 17 (9), 827–833. doi: 10.1089/acm.2010.0716
Ammon, H. P., Muller, P. H., Eggstein, M., Wintermantel, C., Aigner, B., Safayhi, H.,
et al. (1992). Increase in glucose consumption by acetylcysteine during
hyperglycemic clamp. A study with healthy volunteers. Arzneimittelforschung
42 (5), 642–645.
Anderson, J. A., and Weitz, J. I. (2010). Hypercoagulable states. Clin. Chest Med.
31 (4), 659–673. doi: 10.1016/j.ccm.2010.07.004
Anhe, F. F., Roy, D., Pilon, G., Dudonne, S., Matamoros, S., Varin, T. V., et al.
(2015). A polyphenol-rich cranberry extract protectsfrom diet-induced obesity,
insulin resistance and intestinal inflammation in association withincreased
Akkermansia spp. population in the gut microbiota of mice. Gut 64 (6), 872–
883. doi: 10.1136/gutjnl-2014-307142
Aprahamian, T. R., and Sam, F. (2011). Adiponectin in cardiovascular
inflammation and obesity. Int. J. Inflam. 2011, 376909. doi: 10.4061/2011/
376909
Araujo, J. A., Zhang, M., and Yin, F. (2012). Heme oxygenase-1, oxidation,
inflammation, and atherosclerosis. Front. Pharmacol. 3, 119. doi: 10.3389/
fphar.2012.00119
Asai, A., Sugawara, T., Ono, H., and Nagao, A. (2004). Biotransformation of
fucoxanthinol into amarouciaxanthin A in mice and HepG2 cells: formation
and cytotoxicity of fucoxanthin metabolites. Drug Metab. Dispos. 32 (2), 205–
211. doi: 10.1124/dmd.32.2.205
Assari, S., and Bazargan, M. (2019). Baseline Obesity Increases 25-Year Risk of
Mortality due to Cerebrovascular Disease: Role of Race. Int. J. Environ. Res.
Public Health 16 (19). doi: 10.3390/ijerph16193705
Ayer, A., Zarjou, A., Agarwal, A., and Stocker, R. (2016). Heme Oxygenases in
Cardiovascular Health and Disease. Physiol. Rev. 96 (4), 1449–1508. doi:
10.1152/physrev.00003.2016
Tun et al. Antioxidants Ameliorate Obesity Phenotype
Frontiers in Pharmacology | www.frontiersin.org August 2020 | Volume 11 | Article 123414
Babu, P. S., and Srinivasan, K. (1997). Hypolipidemic action of curcumin, the
active principle of turmeric (Curcuma longa) in streptozotocin induced
diabetic rats. Mol. Cell Biochem. 166 (1-2), 169–175. doi: 10.1023/
A:1006819605211
Balla, G., Jacob, H. S., Balla, J., Rosenberg, M., Nath, K., Apple, F., et al. (1992).
Ferritin: a cytoprotective antioxidant strategem of endothelium. J. Biol. Chem.
267 (25), 18148–18153.
Baxter, L. L., Marugan, J. J., Xiao, J., Incao, A., McKew, J. C., Zheng, W., et al.
(2012). Plasma and tissue concentrations of alpha-tocopherol and delta-
tocopherol following high dose dietary supplementation in mice. Nutrients 4
(6), 467–490. doi: 10.3390/nu4060467
Beck, K., Wu, B. J., Ni, J., Santiago, F. S., Malabanan, K. P., Li, C., et al. (2010).
Interplay between heme oxygenase-1 and the multifunctional transcription
factor yin yang 1 in the inhibition of intimal hyperplasia. Circ. Res. 107 (12),
1490–1497. doi: 10.1161/CIRCRESAHA.110.231985
Beppu, F., Hosokawa, M., Niwano, Y., and Miyashita, K. (2012). Effects of dietary
fucoxanthin on cholesterol metabolism in diabetic/obese KK-A(y) mice. Lipids
Health Dis. 11, 112. doi: 10.1186/1476-511X-11-112
Beppu, F., Hosokawa, M., Yim, M. J., Shinoda, T., and Miyashita, K. (2013).
Down-regulation of hepatic stearoyl-CoA desaturase-1 expression by
fucoxanthin via leptin signaling in diabetic/obese KK-A(y) mice. Lipids 48
(5), 449–455. doi: 10.1007/s11745-013-3784-4
Bereczki, D.Jr., Balla, J., and Bereczki, D. (2018). Heme Oxygenase-1: Clinical
Relevance in Ischemic Stroke. Curr. Pharm. Des. 24 (20), 2229–2235. doi:
10.2174/1381612824666180717101104
Berrington de Gonzalez, A., Hartge, P., Cerhan, J. R., Flint, A. J., Hannan, L.,
MacInnis, R. J., et al. (2010). Body-mass index and mortality among
1.46million white adults. N. Engl. J. Med. 363 (23), 2211–2219. doi: 10.1056/
NEJMoa1000367
Berry, D. C., DeSantis, D., Soltanian, H., Croniger, C. M., and Noy, N. (2012).
Retinoic acid upregulates preadipocyte genes to block adipogenesis and
suppress diet-induced obesity. Diabetes 61 (5), 1112–1121. doi: 10.2337/
db11-1620
Beydoun, M. A., Chen, X., Jha, K., Beydoun, H. A., Zonderman, A. B., Canas, J. A.,
et al. (2019). Carotenoids, vitamin A, and their association with the metabolic
syndrome: a systematic review and meta-analysis. Nutr. Rev. 77 (1), 32–45. doi:
10.1093/nutrit/nuy044
Bhatti, J. S., Bhatti, G. K., and Reddy, P. H. (2017). Mitochondrial dysfunction and
oxidative stress in metabolic disorders - A step towards mitochondria based
therapeutic strategies. Biochim. Biophys. Acta Mol. Basis Dis. 1863 (5), 1066–
1077. doi: 10.1016/j.bbadis.2016.11.010
Blokhin, I. O., and Lentz, S. R. (2013). Mechanisms of thrombosis in obesity. Curr.
Opin. Hematol. 20 (5), 437–444. doi: 10.1097/MOH.0b013e3283634443
Bohn, T., Desmarchelier, C., Dragsted, L. O., Nielsen, C. S., Stahl, W., Ruhl, R.,
et al. (2017). Host-related factors explaining interindividual variability of
carotenoid bioavailability and tissue concentrations in humans. Mol. Nutr.
Food Res. 61 (6). doi: 10.1002/mnfr.201600685
Boscoboinik, D., Szewczyk, A., Hensey, C., and Azzi, A. (1991). Inhibition of cell
proliferation by alpha-tocopherol. Role of protein kinase C. J. Biol. Chem. 266
(10), 6188–6194.
Burgess, A., Li, M., Vanella, L., Kim, D. H., Rezzani, R., Rodella, L., et al. (2010).
Adipocyte heme oxygenase-1 induction attenuates metabolic syndrome in
both male and female obese mice. Hypertension 56 (6), 1124–1130. doi:
10.1161/HYPERTENSIONAHA.110.151423
Burhans, M. S., Hagman, D. K., Kuzma, J. N., Schmidt, K. A., and Kratz, M. (2018).
Contribution of Adipose Tissue Inflammation to the Development of Type 2
Diabetes Mellitus. Compr. Physiol. 9 (1), 1–58. doi: 10.1002/cphy.c170040
Calzadilla, P., Sapochnik, D., Cosentino, S., Diz, V., Dicelio, L., Calvo, J. C., et al.
(2011). N-acetylcysteine reduces markers of differentiation in 3T3-L1
adipocytes. Int. J. Mol. Sci. 12 (10), 6936–6951. doi: 10.3390/ijms12106936
Canas, J. A., Lochrie, A., McGowan, A. G., Hossain, J., Schettino, C., and
Balagopal, P. B. (2017). Effects of Mixed Carotenoids on Adipokines and
Abdominal Adiposity in Children: A Pilot Study. J. Clin. Endocrinol. Metab.
102 (6), 1983–1990. doi: 10.1210/jc.2017-00185
Cao, J., Peterson, S. J., Sodhi, K., Vanella, L., Barbagallo, I., Rodella, L. F., et al.
(2012). Heme oxygenase gene targeting to adipocytes attenuates adiposity and
vascular dysfunction in mice fed a high-fat diet. Hypertension 60 (2), 467–475.
doi: 10.1161/HYPERTENSIONAHA.112.193805
Carlsen, H., Haugen, F., Zadelaar, S., Kleemann, R., Kooistra, T., Drevon, C. A.,
et al. (2009). Diet-induced obesity increases NF-kappaB signaling in reporter
mice. Genes Nutr. 4 (3), 215–222. doi: 10.1007/s12263-009-0133-6
Castro-Barquero, S., Lamuela-Raventos, R. M., Domenech, M., and Estruch, R.
(2018). Relationship between Mediterranean Dietary Polyphenol Intake and
Obesity. Nutrients 10 (10). doi: 10.3390/nu10101523
Chait, A., and den Hartigh, L. J. (2020). Adipose Tissue Distribution, Inflammation
and Its Metabolic Consequences, Including Diabetes and Cardiovascular
Disease. Front. Cardiovasc. Med. 7, 22. doi: 10.3389/fcvm.2020.00022
Chan, K. H., Ng, M. K., and Stocker, R. (2011). Haem oxygenase-1 and
cardiovascular disease: mechanisms and therapeutic potential. Clin. Sci.
(Lond) 120 (12), 493–504. doi: 10.1042/CS20100508
Chen, F., Hadfield, J. M., Berzingi, C., Hollander, J. M., Miller, D. B., Nichols, C. E.,
et al. (1985). N-acetylcysteine reverses cardiac myocytedysfunction in a rodent
model of behavioral stress. J. Appl. Physiol. 2013. 115 (4), 514–524. doi:
10.1152/japplphysiol.01471.2012
Cheng, C., Noordeloos, A. M., Jeney, V., Soares, M. P., Moll, F., Pasterkamp, G.,
et al. (2009). Heme oxygenase 1 determines atherosclerotic lesion progression
into a vulnerable plaque. Circulation 119 (23), 3017–3027. doi: 10.1161/
CIRCULATIONAHA.108.808618
Chouchani, E. T., Kazak, L., and Spiegelman, B. M. (2017). Mitochondrial reactive
oxygen species and adipose tissue thermogenesis: Bridging physiology and
mechanisms. J. Biol. Chem. 292 (41), 16810–16816. doi: 10.1074/jbc.R117.789628
Colombo, M. L., and vitamin, E. (2010). tocopherol and tocotrienol-perspectives.
Molecules 15 (4), 2103–2113. doi: 10.3390/molecules15042103
Cook-Mills, J. M., Abdala-Valencia, H., and Hartert, T. (2013). Two faces of
vitamin E in the lung. Am. J. Respir. Crit. Care Med. 188 (3), 279–284. doi:
10.1164/rccm.201303-0503ED
Cook-Mills, J. M. (2013). Isoforms of Vitamin E Differentially Regulate PKC alpha
and Inflammation: A Review. J. Clin. Cell Immunol. 4 (137). doi: 10.4172/2155-
9899.1000137
Coronel, J., Pinos, I., and Amengual, J. (2019). beta-carotene in Obesity Research:
Technical Considerations and Current Status of the Field. Nutrients 11 (4). doi:
10.3390/nu11040842
Craver, B. M., Ramanathan, G., Hoang, S., Chang, X.,Mendez Luque, L. F., Brooks, S.,
et al. (2020). N-acetylcysteine inhibits thrombosis in a murine model of
myeloproliferative neoplasm. Blood Adv. 4 (2), 312–321. doi: 10.1182/
bloodadvances.2019000967
Cui, R., Gao, M., Qu, S., and Liu, D. (2014). Overexpression of superoxide
dismutase 3 gene blocks high-fat diet-induced obesity, fatty liver and insulin
resistance. Gene Ther. 21 (9), 840–848. doi: 10.1038/gt.2014.64
de Almeida, A., de Almeida Rezende, M. S., Dantas, S. H., de Lima Silva, S., de
Oliveira, J., de Lourdes Assuncao Araujo de Azevedo, F., et al. (2020). Unveiling
the Role of Inflammation and Oxidative Stress on Age-Related Cardiovascular
Diseases. Oxid. Med. Cell Longev. 2020, 1954398. doi: 10.1155/2020/1954398
de Andrade, K. Q., Moura, F. A., dos Santos, J. M., de Araujo, O. R., de Farias
Santos, J. C., Goulart, M. O., et al. (2015). Oxidative Stress and Inflammation in
Hepatic Diseases: Therapeutic Possibilities of N-Acetylcysteine. Int. J. Mol. Sci.
16 (12), 30269–30308. doi: 10.3390/ijms161226225
de Mello, A. H., Costa, A. B., Engel, J. D. G., and Rezin, G. T. (2018). Mitochondrial
dysfunction in obesity. Life Sci. 192, 26–32. doi: 10.1016/j.lfs.2017.11.019
Dela Cruz, C. S., and Kang, M. J. (2018). Mitochondrial dysfunction and damage
associated molecular patterns (DAMPs) in chronic inflammatory diseases.
Mitochondrion 41, 37–44. doi: 10.1016/j.mito.2017.12.001
Diniz, Y. S., Rocha, K. K., Souza, G. A., Galhardi, C. M., Ebaid, G. M., Rodrigues,
H. G., et al. (2006). Effects of N-acetylcysteine on sucrose-rich diet-induced
hyperglycaemia, dyslipidemia and oxidative stress in rats. Eur. J. Pharmacol.
543 (1-3), 151–157. doi: 10.1016/j.ejphar.2006.05.039
Dludla, P. V., Nkambule, B. B., Dias, S. C., and Johnson, R. (2017).
Cardioprotective potential of N-acetyl cysteine against hyperglycaemia-
induced oxidative damage: a protocol for a systematic review. Syst. Rev. 6
(1), 96. doi: 10.1186/s13643-017-0493-8
Donohoe, F., Wilkinson, M., Baxter, E., and Brennan, D. J. (2020). Mitogen-
Activated Protein Kinase (MAPK) and Obesity-Related Cancer. Int. J. Mol. Sci.
21 (4). doi: 10.3390/ijms21041241
Durante, W. (2003). Heme oxygenase-1 in growth control and its clinical
application to vascular disease. J. Cell Physiol. 195 (3), 373–382. doi:
10.1002/jcp.10274
Tun et al. Antioxidants Ameliorate Obesity Phenotype
Frontiers in Pharmacology | www.frontiersin.org August 2020 | Volume 11 | Article 123415
Durante, W. (2011). Protective role of heme oxygenase-1 against inflammation in
atherosclerosis. Front. Biosci. (Landmark Ed) 16, 2372–2388. doi: 10.2741/3860
Dutra, F. F., and Bozza, M. T. (2014). Heme on innate immunity and
inflammation. Front. Pharmacol. 5:115. doi: 10.3389/fphar.2014.00115
Dutton, S., and Trayhurn, P. (2008). Regulation of angiopoietin-like protein 4/
fasting-induced adipose factor (Angptl4/FIAF) expression in mouse white
adipose tissue and 3T3-L1 adipocytes. Br. J. Nutr. 100 (1), 18–26. doi: 10.1017/
S0007114507882961
Eder, K., Keller, U., and Brandsch, C. (2004). Effects of a dietary oxidized fat on
cholesterol in plasma and lipoproteins and the susceptibility of low-density
lipoproteins to lipid peroxidation in guinea pigs fed diets with different
concentrations of vitamins E and C. Int. J. Vitam Nutr. Res. 74 (1), 11–20.
doi: 10.1024/0300-9831.74.1.11
Engin, K. N. (2009). Alpha-tocopherol: looking beyond an antioxidant. Mol. Vis.
15, 855–860.
Fisher, A. B. (2018). The phospholipase A2 activity of peroxiredoxin 6. J. Lipid Res.
59 (7), 1132–1147. doi: 10.1194/jlr.R082578
Fonseca-Alaniz, M. H., et al. (2007). Adipose tissue as an endocrine organ: from
theory to practice. J. Pediatr. (Rio J) 83 (5 Suppl), S192–S203. doi: 10.2223/
JPED.1709
Fraga, C. G., Croft, K. D., Kennedye, D. O., and Tomás-Barberán, F. A. (2019). The
effects of polyphenols and other bioactives on human health. Food Funct. 10
(2), 514–528. doi: 10.1039/C8FO01997E
Friedman, J. M., and Halaas, J. L. (1998). Leptin and the regulation of body weight
inmammals. Nature 395 (6704), 763–770. doi: 10.1038/27376
Frismantiene, A., Philippova, M., Erne, P., and Resink, T. J. (2018). Smooth muscle
cell-driven vascular diseases and molecular mechanisms of VSMC plasticity.
Cell Signal 52, 48–64. doi: 10.1016/j.cellsig.2018.08.019
Fruh, S. M. (2017). Obesity: Risk factors, complications, and strategies for
sustainable long-term weight management. J. Am. Assoc. Nurse Pract. 29
(S1), S3–S14. doi: 10.1002/2327-6924.12510
Fukai, T., and Ushio-Fukai, M. (2011). Superoxide dismutases: role in redox
signaling, vascular function, and diseases. Antioxid. Redox Signal 15 (6), 1583–
1606. doi: 10.1089/ars.2011.3999
Fulghesu, A. M., Ciampelli, M., Muzj, G., Belosi, C., Selvaggi, L., Ayala, G. F., et al.
(2002). N-acetyl-cysteine treatment improves insulin sensitivity in women
with polycystic ovary syndrome. Fertil. Steril. 77 (6), 1128–1135. doi: 10.1016/
S0015-0282(02)03133-3
Furchgott, R. F., and Jothianandan, D. (1991). Endothelium-dependent and
-independent vasodilation involving cyclic GMP: relaxation induced by
nitric oxide, carbon monoxide and light. Blood Vessels 28 (1-3), 52–61. doi:
10.1159/000158843
Galiniak, S.,Aebisher,D., andBartusik-Aebisher,D. (2019).Healthbenefits of resveratrol
administration. Acta Biochim. Pol. 66 (1), 13–21. doi: 10.18388/abp.2018_2749
Galmes, S., Serra, F., and Palou, A. (2018). Vitamin E Metabolic Effects and
Genetic Variants: A Challenge for Precision Nutrition in Obesity and
Associated Disturbances. Nutrients 10 (12). doi: 10.3390/nu10121919
Gibson, K. R., Winterburn, T. J., Barrett, F., Sharma, S., MacRury, S. M., and
Megson, I. L. (2011). Therapeutic potential of N-acetylcysteine as an
antiplatelet agent in patients with type-2 diabetes. Cardiovasc. Diabetol. 10,
43. doi: 10.1186/1475-2840-10-43
Girouard, H., Chulak, C., Wu, L., Lejossec, M., and de Champlain, J. (2003). N-
acetylcysteine improves nitric oxide and alpha-adrenergic pathways in
mesenteric beds of spontaneously hypertensive rats. Am. J. Hypertens. 16 (7),
577–584. doi: 10.1016/S0895-7061(03)00863-X
Gozzelino, R., Jeney, V., and Soares, M. P. (2010). Mechanisms of cell protection
by heme oxygenase-1. Annu. Rev. Pharmacol. Toxicol. 50, 323–354. doi:
10.1146/annurev.pharmtox.010909.105600
Grigsby, R. J., and Dobrowsky, R. T. (2001). Inhibition of ceramide production
reverses TNF-induced insulin resistance. Biochem. Biophys. Res. Commun. 287
(5), 1121–1124. doi: 10.1006/bbrc.2001.5694
Haczeyni, F., Bell-Anderson, K. S., and Farrell, G. C. (2018). Causes and
mechanisms of adipocyte enlargement and adipose expansion. Obes. Rev. 19
(3), 406–420. doi: 10.1111/obr.12646
Haleagrahara, N., Julian, V., and Chakravarthi, S. (2011). N-acetylcysteine offers
cardioprotection by decreasing cardiac lipid hydroperoxides and 8-isoprostane
level in isoproterenol-induced cardiotoxicity in rats. Cardiovasc. Toxicol. 11
(4), 373–381. doi: 10.1007/s12012-011-9132-0
Hall, A., Karplus, P. A., and Poole, L. B. (2009). Typical 2-Cys peroxiredoxins–
structures, mechanisms and functions. FEBS J. 276 (9), 2469–2477. doi:
10.1111/j.1742-4658.2009.06985.x
Hammarstedt, A., Gogg, S., Hedjazifar, S., Nerstedt, A., and Smith, U. (2018).
Impaired Adipogenesis and Dysfunctional Adipose Tissue in Human
Hypertrophic Obesity. Physiol. Rev. 98 (4), 1911–1941. doi: 10.1152/
physrev.00034.2017
Hashimoto, T., Ozaki, Y., Taminato,M., Das, S. K., Mizuno, M., Yoshimura, K., et al.
(2009). The distribution and accumulation of fucoxanthin and its metabolites
after oral administration in mice. Br. J. Nutr. 102 (2), 242–248. doi: 10.1017/
S0007114508199007
Heeba, G., Moselhy, M. E., Hassan, M., Khalifa, M., Gryglewski, R., and Malinski, T.
(2009). Anti-atherogenic effect of statins: role of nitric oxide, peroxynitrite and
haem oxygenase-1. Br. J. Pharmacol. 156 (8), 1256–1266. doi: 10.1111/j.1476-
5381.2009.00125.x
Hennig, B., Lei, W., Arzuaga, X., Ghosh, D. D., Saraswathi, V., and Toborek, M.
(2006). Linoleic acid induces proinflammatory events in vascular endothelial
cells via activation of PI3K/Akt and ERK1/2 signaling. J. Nutr. Biochem. 17
(11), 766–772. doi: 10.1016/j.jnutbio.2006.01.005
Hernandez-Corbacho, M. J., Canals, D., Adada, M. M., Liu, M., Senkal, C. E., Yi, J. K.,
et al. (2015). Tumor Necrosis Factor-alpha (TNFalpha)-induced Ceramide
Generation via Ceramide Synthases Regulates Loss of Focal Adhesion Kinase
(FAK) and Programmed Cell Death. J. Biol. Chem. 290 (42), 25356–25373. doi:
10.1074/jbc.M115.658658
Hosick, P. A., and Stec, D. E. (2012). Heme oxygenase, a novel target for the
treatmentof hypertension and obesity? Am. J. Physiol. Regul. Integr. Comp.
Physiol. 302 (2), R207–R214. doi: 10.1152/ajpregu.00517.2011
Houtkooper, R. H., Pirinen, E., and Auwerx, J. (2012). Sirtuins as regulators of
metabolism and healthspan. Nat. Rev. Mol. Cell Biol. 13 (4), 225–238. doi:
10.1038/nrm3293
Hruby, A., and Hu, F. B. (2015). The Epidemiology of Obesity: A Big Picture.
Pharmacoeconomics 33 (7), 673–689. doi: 10.1007/s40273-014-0243-x
Hu, X., Li, Y., Li, C., Fu, Y., Cai, F., Chen, Q., et al. (2012). Combination of
fucoxanthin and conjugated linoleic acid attenuates body weight gain and
improves lipid metabolism in high-fat diet-induced obese rats. Arch. Biochem.
Biophys. 519 (1), 59–65. doi: 10.1016/j.abb.2012.01.011
Huang, J., Wang, Y., Xie, Z., Zhou, Y., Zhang, Y., and Wan, X. (2014). The anti-
obesity effects of green tea in human intervention and basic molecular studies.
Eur. J. Clin. Nutr. 68 (10), 1075–1087. doi: 10.1038/ejcn.2014.143
Huang, J., Weinstein, S. J, Yu, K., Mannisto, S., and Albanes, D. (2018). Serum Beta
Carotene and Overall and Cause-Specific Mortality. Circ. Res. 123 (12), 1339–1349.
doi: 10.1161/CIRCRESAHA.118.313409
Huh, J. Y., Kim, Y., Jeong, J., Park, J., Kim, I., Huh, K. H., et al. (2012).
Peroxiredoxin 3 is a key molecule regulating adipocyte oxidative stress,
mitochondrial biogenesis, and adipokine expression. Antioxid. Redox Signal
16 (3), 229–243. doi: 10.1089/ars.2010.3766
Hwang, S. L., Jeong, Y. T., Li, X., Kim, Y. D., Lu, Y., Chang, Y. C., et al. (2013).
Inhibitory cross-talk between the AMPK and ERK pathways mediates
endoplasmic reticulum stress-induced insulin resistance in skeletal muscle.
Br. J. Pharmacol. 169 (1), 69–81. doi: 10.1111/bph.12124
Ighodaro, O. M. (2018). Molecular pathways associated with oxidative stress in
diabetes mellitus. BioMed. Pharmacother. 108, 656–662. doi: 10.1016/
j.biopha.2018.09.058
Jaoude, J., and Koh, Y. (2016). Matrix metalloproteinases in exercise and obesity.
Vasc. Health Risk Manag. 12, 287–295. doi: 10.2147/VHRM.S103877
Johnson, Q. R., Mostofian, B., Fuente Gomez, G., Smith, J. C., Cheng, X., Johnson,
Q. R., et al. (2018). Effects of carotenoids on lipid bilayers. Phys. Chem. Chem.
Phys. 20 (5), 3795–3804. doi: 10.1039/C7CP07126D
Kachur, S., Lavie, C. J., de Schutter, A., Milani, R. V., and Ventura, H. O. (2017).
Obesity and cardiovasculardiseases. Minerva Med. 108 (3), 212–228. doi:
10.23736/S0026-4806.17.05022-4
Kang, S. I., Ko, H. C., Shin, H. S., Kim, H. M., Hong, Y. S., Lee, N. H., et al. (2011).
Fucoxanthin exerts differing effects on 3T3-L1 cells according to differentiation
stage and inhibits glucose uptake in mature adipocytes. Biochem. Biophys. Res.
Commun. 409 (4), 769–774. doi: 10.1016/j.bbrc.2011.05.086
Kawanaka, M., Nishino, K., Nakamura, J., Suehiro, M., Goto, D., Urata, N., et al.
(2013). Treatment of nonalcoholic steatohepatitis with vitamins E and C: a
pilot study. Hepat. Med. 5, 11–16. doi: 10.2147/HMER.S41258
Tun et al. Antioxidants Ameliorate Obesity Phenotype
Frontiers in Pharmacology | www.frontiersin.org August 2020 | Volume 11 | Article 123416
Kerksick, C., and Willoughby, D. (2005). The antioxidant role of glutathione and
N-acetyl-cysteine supplements and exercise-induced oxidative stress. J. Int.
Soc. Sports Nutr. 2, 38–44. doi: 10.1186/1550-2783-2-2-38
Khan, N., and Mukhtar, H. (2018). Tea Polyphenols in Promotion of Human
Health. Nutrients 11 (1). doi: 10.3390/nu11010039
Khitan, Z., Harsh, M., Sodhi, K., Shapiro, J. I., and Abraham, N. G. (2014). HO-1
Upregulation Attenuates Adipocyte Dysfunction, Obesity, and Isoprostane
Levels in Mice Fed High Fructose Diets. J. Nutr. Metab. 2014, 980547. doi:
10.1155/2014/980547
Kim, J. Y., van deWall, E., Laplante, M., Azzara, A., Trujillo,M. E., Hofmann, S.M., et al.
(2007). Obesity-associated improvements in metabolic profile through expansion of
adipose tissue. J. Clin. Invest. 117 (9), 2621–2637. doi: 10.1172/JCI31021
Kim, D. H., Burgess, A. P., Li, M., Tsenovoy, P. L., Addabbo, F., McClung, J. A., et al.
(2008). Heme oxygenase-mediated increases in adiponectin decrease fat content
and inflammatory cytokines tumor necrosis factor-alpha and interleukin-6 in
Zucker rats and reduce adipogenesis in human mesenchymal stem cells. J.
Pharmacol. Exp. Ther. 325 (3), 833–840. doi: 10.1124/jpet.107.135285
Kim, M. H., Park, S. J., Kim, J. H., Seong, J. B., Kim, K. M., Woo, H. A., et al.
(2018). Peroxiredoxin 5 regulates adipogenesis-attenuating oxidative stress in
obese mouse models induced by a high-fat diet. Free Radic. Biol. Med. 123, 27–
38. doi: 10.1016/j.freeradbiomed.2018.05.061
Kim, M. H., Seong, J. B., Huh, J. W., Bae, Y. C., Lee, H. S., Lee, D. S., et al. (2020).
Peroxiredoxin 5 ameliorates obesity-induced non-alcoholic fatty liver disease
through the regulation of oxidative stress and AMP-activated protein kinase
signaling. Redox Biol. 28, 101315. doi: 10.1016/j.redox.2019.101315
Kirmizis, D., and Chatzidimitriou, D. (2009). Antiatherogenic effects of vitamin E:
the search for the Holy Grail. Vasc. Health Risk Manag. 5, 767–774. doi:
10.2147/VHRM.S5532
Korou, L. M., Agrogiannis, G., Pantopoulou, A., Vlachos, I. S., Iliopoulos, D.,
Karatzas, T., et al. (2010). Comparative antilipidemic effect of N-acetylcysteine
and sesame oil administration in diet-induced hypercholesterolemic mice.
Lipids Health Dis. 9, 23. doi: 10.1186/1476-511X-9-23
Korou, L. M., Agrogiannis, G., Koros, C., Kitraki, E., Vlachos, I. S., Tzanetakou, I.,
et al. (2014). Impact of N-acetylcysteine and sesame oil on lipid metabolism
and hypothalamic-pituitary-adrenal axis homeostasis in middle-aged
hypercholesterolemic mice. Sci. Rep. 4, 6806. doi: 10.1038/srep06806
Kruger, A. L., Peterson, S. J., Schwartzman, M. L., Fusco, H., McClung, J. A., Weiss, M.,
et al. (2006). Up-regulation of heme oxygenase provides vascular protection in an
animal model of diabetes through its antioxidant and antiapoptotic effects. J.
Pharmacol. Exp. Ther. 319 (3), 1144–1152. doi: 10.1124/jpet.106.107482
Kuk, J. L., Ardern, C.II, Church, T. S., Sharma, A. M., Padwal, R., Sui, X., et al.
(2011). Edmonton Obesity Staging System: association with weight history
and mortality risk. Appl. Physiol. Nutr. Metab. 36 (4), 570–576. doi: 10.1139/
h11-058
Kumar, S., and Bandyopadhyay, U. (2005). Free heme toxicity and its
detoxification systems in human. Toxicol. Lett. 157 (3), 175–188. doi:
10.1016/j.toxlet.2005.03.004
Kuroda, M., and Sakaue, H. (2017). Adipocyte Death and Chronic Inflammation
in Obesity. J. Med. Invest. 64 (3.4), 193–196. doi: 10.2152/jmi.64.193
Kuroda, J., Ago, T., Matsushima, S., Zhai, P., Schneider, M. D., and Sadoshima, J.
(2010). NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the
failing heart. Proc. Natl. Acad. Sci. U.S.A. 107 (35), 15565–15570. doi: 10.1073/
pnas.1002178107
Kuznetsov, N. S., Abulela, A. M., and Neskoromnyi, V. N. (1993). [The use of
antioxidants (alpha-tocopherol acetate) in the treatment of diabetes mellitus].
Probl. Endokrinol. (Mosk) 39 (2), 9–11. doi: 10.14341/probl11942
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F.,
et al. (2006). Resveratrol improves mitochondrial function and protects against
metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127 (6), 1109–
1122. doi: 10.1016/j.cell.2006.11.013
Lakhani, H. V., Sharma, D., Dodrill, M. W., Nawab, A., Sharma, N., Cottrill, C. L.,
et al. (2018). Phenotypic Alteration of Hepatocytes in Non-Alcoholic Fatty
Liver Disease. Int. J. Med. Sci. 15 (14), 1591–1599. doi: 10.7150/ijms.27953
Langi, P., Kiokias, S., Varzakas, T., and Proestos, C. (2018). Carotenoids: From
Plants to Food and Feed Industries. Methods Mol. Biol. 1852, 57–71. doi:
10.1007/978-1-4939-8742-9_3
Lasram, M. M., Dhouib, I. B., Annabi, A., El Fazaa, S., and Gharbi, N. (2015). A
review on the possible molecular mechanism of action of N-acetylcysteine
against insulin resistance and type-2 diabetes development. Clin. Biochem. 48
(16-17), 1200–1208. doi: 10.1016/j.clinbiochem.2015.04.017
Lauby-Secretan, B., Dossus, L., Marant-Micallef, C., and His, M. (2019). [Obesity
and Cancer]. Bull. Cancer 106 (7-8), 635–646. doi: 10.1016/j.bulcan.2019.04.008
Lauhio, A., Farkkila, E., Pietilainen, K. H., Astrom, P., Winkelmann, A.,
Tervahartiala, T., et al. (2016). Association of MMP-8 with obesity, smoking
and insulin resistance. Eur. J. Clin. Invest. 46 (9), 757–765. doi: 10.1111/
eci.12649
Lee, G. Y., and Han, S. N. (2018). The Role of Vitamin E in Immunity.Nutrients 10
(11). doi: 10.3390/nu10111614
Lee, I. K., Koya, D., Ishi, H., Kanoh, H., and King, G. L. (1999). d-Alpha-
tocopherol prevents the hyperglycemia induced activation of diacylglycerol
(DAG)-protein kinase C (PKC) pathway in vascular smooth muscle cell by an
increase of DAG kinase activity. Diabetes Res. Clin. Pract. 45 (2-3), 183–190.
doi: 10.1016/S0168-8227(99)00048-0
Lee, H., Lee, Y. J., Choi, H., Ko, E. H., and Kim, J. W. (2009). Reactive oxygen
species facilitate adipocyte differentiation by accelerating mitotic clonal
expansion. J. Biol. Chem. 284 (16), 10601–10609. doi: 10.1074/jbc.M808742200
Lee, M. J., Wu, Y., and Fried, S. K. (2010). Adipose tissue remodeling in
pathophysiology of obesity. Curr. Opin. Clin. Nutr. Metab. Care 13 (4), 371–
376. doi: 10.1097/MCO.0b013e32833aabef
Lee, D. H., Jung, Y. Y., Park, M. H., Jo, M. R., Han, S. B., Yoon, D. Y., et al. (2019).
Peroxiredoxin 6 Confers Protection Against Nonalcoholic Fatty Liver Disease
Through Maintaining Mitochondrial Function. Antioxid. Redox Signal 31 (5),
387–402. doi: 10.1089/ars.2018.7544
Lenoir, O., Gaillard, F., Lazareth, H., Robin, B., and Tharaux, P. L. (2017). Hmox1
Deficiency Sensitizes Mice to Peroxynitrite Formation and Diabetic Glomerular
Microvascular Injuries. J. Diabetes Res. 2017, 9603924. doi: 10.1155/2017/9603924
Leopoldini, M., Malaj, N., Toscano, M., Sindona, G., and Russo, N. (2010). On the
inhibitor effects of bergamot juice flavonoids binding to the 3-hydroxy-3-
methylglutaryl-CoA reductase (HMGR) enzyme. J. Agric. Food Chem. 58 (19),
10768–10773. doi: 10.1021/jf102576j
Lettieri-Barbato, D. (2019). Redox control of non-shivering thermogenesis. Mol.
Metab. 25, 11–19. doi: 10.1016/j.molmet.2019.04.002
Lewis, E. D., Meydani, S. N., and Wu, D. (2019). Regulatory role of vitamin E in
the immune system and inflammation. IUBMB Life 71 (4), 487–494. doi:
10.1002/iub.1976
Li, M., Kim, D. H., Tsenovoy, P. L., Peterson, S. J., Rezzani, R., Rodella, L. F., et al.
(2008). Treatment of obese diabetic mice with a heme oxygenase inducer
reduces visceral and subcutaneous adiposity, increases adiponectin levels, and
improves insulin sensitivity and glucose tolerance. Diabetes 57 (6), 1526–1535.
doi: 10.2337/db07-1764
Li, X., Li, S., Chen, M., Wang, J., Xie, B., and Sun, Z. (2018). (-)-Epigallocatechin-3-
gallate (EGCG) inhibits starch digestion and improves glucose homeostasis
through direct or indirect activation of PXR/CAR-mediated phase II metabolism
in diabetic mice. Food Funct. 9 (9), 4651–4663. doi: 10.1039/C8FO01293H
Libby, P. (2006). Inflammation and cardiovascular disease mechanisms. Am. J.
Clin. Nutr. 83 (2), 456S–460S. doi: 10.1093/ajcn/83.2.456S
Lin, C. C., and Yin, M. C. (2008). Effects of cysteine-containing compounds on
biosynthesis of triacylglycerol and cholesterol and anti-oxidative protection in
liver from mice consuming a high-fat diet. Br. J. Nutr. 99 (1), 37–43. doi:
10.1017/S0007114507793881
Lin, T. H., Chun,, and Kang, L. (2016). Adipose extracellular matrix remodelling in
obesity and insulin resistance. Biochem. Pharmacol. 119, 8–16. doi: 10.1016/
j.bcp.2016.05.005
Lira, F. S., Rosa, J. C., Cunha, C. A., Ribeiro, E. B., do Nascimento, C. O., Oyama, L. M.,
et al. (2011). Supplementing alpha-tocopherol (vitamin E) and vitamin D3 in high
fat diet decrease IL-6 production in murine epididymal adipose tissue and 3T3-L1
adipocytes following LPS stimulation. Lipids Health Dis. 10, 37. doi: 10.1186/1476-
511X-10-37
Lone, J., Choi, J. H., Kim, S. W., and Yun, J. W. (2016). Curcumin induces brown
fat-like phenotype in 3T3-L1 and primary white adipocytes. J. Nutr. Biochem.
27, 193–202. doi: 10.1016/j.jnutbio.2015.09.006
Ma, Y., Gao, M., and Liu, D. (2016). N-acetylcysteine Protects Mice from High Fat
Diet-induced Metabolic Disorders. Pharm. Res. 33 (8), 2033–2042. doi:
10.1007/s11095-016-1941-1
Maeda, H., Hosokawa, M., Sashima, T., Funayama, K., and Miyashita, K. (2005).
Fucoxanthin from edible seaweed, Undaria pinnatifida, shows antiobesity effect
Tun et al. Antioxidants Ameliorate Obesity Phenotype
Frontiers in Pharmacology | www.frontiersin.org August 2020 | Volume 11 | Article 123417
through UCP1 expression in white adipose tissues. Biochem. Biophys. Res.
Commun. 332 (2), 392–397. doi: 10.1016/j.bbrc.2005.05.002
Makhoul, Z., Kristal, A. R., Gulati, R., Luick, B., Bersamin, A., O'Brien, D., et al.
(2011). Associations of obesity with triglycerides and C-reactive protein are
attenuated in adults with high red blood cell eicosapentaenoic and
docosahexaenoic acids. Eur. J. Clin. Nutr. 65 (7), 808–817. doi: 10.1038/
ejcn.2011.39
Manna, P., and Jain, S. K. (2015). Obesity, Oxidative Stress, Adipose Tissue
Dysfunction, and the Associated Health Risks: Causes and Therapeutic
Strategies. Metab. Syndr. Relat. Disord. 13 (10), 423–444. doi: 10.1089/
met.2015.0095
Martinez de Lizarrondo, S., Gakuba, C., Herbig, B. A., Repesse, Y., Ali, C., Denis,
C. V., et al. (2017). Potent Thrombolytic Effect of N-Acetylcysteine on Arterial
Thrombi. Circulation 136 (7), 646–660. doi: 10.1161/CIRCULATIONAHA.
117.027290
Martin-Nizard, F., Boullier, A., Fruchart, J. C., and Duriez P. (1998). Alpha-
tocopherol but not beta-tocopherol inhibits thrombin-induced PKC activation
and endothelin secretion in endothelial cells. J. Cardiovasc. Risk 5 (5-6), 339–
345. doi: 10.1177/174182679800500510
McKenna, M. J., Medved, I., Goodman, C. A., Brown, M. J., Bjorksten, A. R., Murphy,
K. T., et al. (2006). N-acetylcysteine attenuates the decline in muscle Na+,K+-pump
activity and delays fatigue during prolonged exercise in humans. J. Physiol. 576 (Pt
1), 279–288. doi: 10.1113/jphysiol.2006.115352
McMurray, F., Patten, D. A., and Harper, M. E. (2016). Reactive Oxygen Species
and Oxidative Stress in Obesity-Recent Findings and Empirical Approaches.
Obes. (Silver Spring) 24 (11), 2301–2310. doi: 10.1002/oby.21654
Mehmeti, I., Lortz, S., Elsner, M., and Lenzen, S. (2014). Peroxiredoxin 4 improves
insulin biosynthesis and glucose-induced insulin secretion in insulin-secreting
INS-1E cells. J. Biol. Chem. 289 (39), 26904–26913. doi: 10.1074/
jbc.M114.568329
Mehmetoglu, I., Yerlikaya, F. H., and Kurban, S. (2011). Correlation between
vitamin A, E, coenzyme Q(10) and degree of insulin resistance in obese and
non-obese subjects. J. Clin. Biochem. Nutr. 49 (3), 159–163. doi: 10.3164/
jcbn.11-08
Miao, L., and St Clair, D. K. (2009). Regulation of superoxide dismutase genes:
implications in disease. Free Radic. Biol. Med. 47 (4), 344–356. doi: 10.1016/
j.freeradbiomed.2009.05.018
Mittendorfer, B., Magkos, F., Fabbrini, E., Mohammed, B. S., and Klein, S. (2009).
Relationship between body fat mass and free fatty acid kinetics in men and
women. Obes. (Silver Spring) 17 (10), 1872–1877. doi: 10.1038/oby.2009.224
Mohammed, M. S., Sendra, S., Lloret, J., and Bosch, I. (2018). Systems and
WBANs for Controlling Obesity. J. Healthc. Eng. 2018, 1564748. doi:
10.1155/2018/1564748
Mokhtari, V., Afsharian, P., Shahhoseini, M., Kalantar, S. M., and Moini, A. (2017). A
Review on Various Uses of N-Acetyl Cysteine. Cell J. 19 (1), 11–17. doi: 10.22074/
cellj.2016.4872
Moncada, S., and Vane, J. R. (1979). The role of prostacyclin in vascular tissue.
Fed. Proc. 38 (1), 66–71.
Montonen, J., Knekt, P., Jarvinen, R., and Reunanen, A. (2004). Dietary
antioxidant intake and risk of type 2 diabetes. Diabetes Care 27 (2), 362–
366. doi: 10.2337/diacare.27.2.362
Moran, N. E., Mohn, E. S., Hason, N., Erdman, J. W.Jr., and Johnson, E. J. (2018).
Intrinsic and Extrinsic Factors Impacting Absorption, Metabolism, and Health
Effects of Dietary Carotenoids. Adv. Nutr. 9 (4), 465–492. doi: 10.1093/
advances/nmy025
Munzel, T., Camici, G. G., Maack, C., Bonetti, N. R., Fuster, V., and Kovacic, J. C.
(2017). Impact of Oxidative Stress on the Heart and Vasculature: Part 2 of a 3-
Part Series. J. Am. Coll. Cardiol. 70 (2), 212–229. doi: 10.1016/j.jacc.
2017.05.035
Murer, S. B., Aeberli, I., Braegger, C. P., Gittermann, M., Hersberger, M., Leonard,
S. W., et al. (2014). Antioxidant supplements reduced oxidative stress and
stabilized liver function tests but did not reduce inflammation in a randomized
controlled trial in obese children and adolescents. J. Nutr. 144 (2), 193–201.
doi: 10.3945/jn.113.185561
Musolino, V., Gliozzi, M., Nucera, S., Carresi, C., Maiuolo, J., Mollace, R., et al.
(2019). The effect of bergamot polyphenolic fraction on lipid transfer protein
system and vascular oxidative stress in a rat model of hyperlipemia. Lipids
Health Dis. 18 (1), 115. doi: 10.1186/s12944-019-1061-0
Musolino, V., Gliozzi, M., Scarano, F., Bosco, F., Scicchitano, M., Nucera, S., et al.
(2020). Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological
Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease. Sci. Rep. 10
(1), 2565. doi: 10.1038/s41598-020-59485-3
Nakashima, Y., Raines, E. W., Plump, A. S., Breslow, J. L., and Ross, R. (1998).
Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the
endothelium in the ApoE-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 18
(5), 842–851. doi: 10.1161/01.ATV.18.5.842
Nath, K. A. (2006). Heme oxygenase-1: a provenance for cytoprotective pathways
in the kidney and other tissues. Kidney Int. 70 (3), 432–443. doi: 10.1038/
sj.ki.5001565
Niki, E. (2015). Evidence for beneficial effects of vitamin E. Korean J. Intern Med.
30 (5), 571–579. doi: 10.3904/kjim.2015.30.5.571
Ollinger, R., Bilban, M., Erat, A., Froio, A., McDaid, J., Tyagi, S., et al. (2005).
Bilirubin: a natural inhibitor of vascular smooth muscle cell proliferation.
Circulation 112 (7), 1030–1039. doi: 10.1161/CIRCULATIONAHA.
104.528802
Oyewole, A. O., and Birch-Machin, M. A. (2015). Mitochondria-targeted
antioxidants. FASEB J. 29 (12), 4766–4771. doi: 10.1096/fj.15-275404
Pacifici, F., Arriga, R., Sorice, G. P., Capuani, B., Scioli, M. G., Pastore, D., et al.
(2014). Peroxiredoxin 6, a novel player in the pathogenesis of diabetes.
Diabetes 63 (10), 3210–3220. doi: 10.2337/db14-0144
Pae, H. O., and Chung, H. T. (2009). Heme oxygenase-1: its therapeutic roles in
inflammatory diseases. Immune Netw. 9 (1), 12–19. doi: 10.4110/in.2009.9.1.12
Pae, H. O., Oh, G. S., Choi, B. M., Chae, S. C., Kim, Y. M., Chung, K. R., et al.
(2004). Carbon monoxide produced by heme oxygenase-1 suppresses T cell
proliferation via inhibition of IL-2 production. J. Immunol. 172 (8), 4744–4751.
doi: 10.4049/jimmunol.172.8.4744
Paine, A., Eiz-Vesper, B., Blasczyk, R., and Immenschuh, S. (2010). Signaling to
heme oxygenase-1 and its anti-inflammatory therapeutic potential. Biochem.
Pharmacol. 80 (12), 1895–1903. doi: 10.1016/j.bcp.2010.07.014
Patrick, L., and Uzick, M. (2001). Cardiovascular disease: C-reactive protein and
the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-
tocopherol, red yeast rice, and olive oil polyphenols. A. Rev. Literature Altern.
Med. Rev. 6 (3), 248–271.
Perkins, A., Nelson, K. J., Parsonage, D., Poole, L. B., and Karplus, P. A. (2015).
Peroxiredoxins: guardians against oxidative stress and modulators of peroxide
signaling. Trends Biochem. Sci. 40 (8), 435–445. doi: 10.1016/j.tibs.2015.05.001
Perriotte-Olson, C., Adi, N., Manickam, D. S., Westwood, R. A., Desouza, C. V.,
Natarajan, G., et al. (2016). Nanoformulated copper/zinc superoxide dismutase
reduces adipose inflammation in obesity. Obes. (Silver Spring) 24 (1), 148–156.
doi: 10.1002/oby.21348
Peterson, S. J., Rubinstein, R., Faroqui, M., Raza, A., Boumaza, I., Zhang, Y., et al.
(2019). Positive Effects of Heme Oxygenase Upregulation on Adiposity and
Vascular Dysfunction: Gene Targeting vs. Pharmacologic Therapy. Int. J. Mol.
Sci. 20 (10). doi: 10.3390/ijms20102514
Peterson, S. J., Dave, N., and Kothari, J. (2020). The Effects of Heme Oxygenase
Upregulation on Obesity and the Metabolic Syndrome. Antioxid. Redox Signal
32 (14), 1061–1070. doi: 10.1089/ars.2019.7954
Poss, K. D., and Tonegawa, S. (1997). Heme oxygenase 1 is required for
mammalian iron reutilization. Proc. Natl. Acad. Sci. U.S.A. 94 (20), 10919–
10924. doi: 10.1073/pnas.94.20.10919
Pratt, R., Lakhani, H. V., Zehra, M., Desauguste, R., Pillai, S. S., and Sodhi, K.
(2019). Mechanistic Insight of Na/K-ATPase Signaling and HO-1 into Models
of Obesity and Nonalcoholic Steatohepatitis. Int. J. Mol. Sci. 21 (1). doi:
10.3390/ijms21010087
Randle, P. J., Garland, P. B., Newsholme, E. A., and Hales, C. N. (1965). The
glucose fatty acid cycle in obesity and maturity onset diabetes mellitus. Ann. N.
Y. Acad. Sci. 131 (1), 324–333. doi: 10.1111/j.1749-6632.1965.tb34800.x
Rao, D. S., Sekhara, N. C., Satyanarayana, M. N., and Srinivasan, M. (1970). Effect
of curcumin on serum and liver cholesterol levels in the rat. J. Nutr. 100 (11),
1307–1315. doi: 10.1093/jn/100.11.1307
Ray, I., Mahata, S. K., and De, R. K. (2016). Obesity: An Immunometabolic
Perspective. Front. Endocrinol. (Lausanne) 7:157. doi: 10.3389/fendo.
2016.00157
Rhee, S. G., Woo, H. A., Kil, I. S., and Bae, S. H. (2012). Peroxiredoxin functions as
a peroxidase and a regulator and sensor of local peroxides. J. Biol. Chem. 287
(7), 4403–4410. doi: 10.1074/jbc.R111.283432
Tun et al. Antioxidants Ameliorate Obesity Phenotype
Frontiers in Pharmacology | www.frontiersin.org August 2020 | Volume 11 | Article 123418
Rhee, S. G. (2016). Overview on Peroxiredoxin. Mol. Cells 39 (1), 1–5. doi:
10.14348/molcells.2016.2368
Richie, J. P. Jr., Nichenametla, S., Neidig, W., Calcagnotto, A., Haley, J. S., Schell,
T. D., et al. (2015). Randomized controlled trial of oral glutathione
supplementation on body stores of glutathione. Eur. J. Nutr. 54 (2), 251–
263. doi: 10.1007/s00394-014-0706-z
Rizvi, S., Raza, S. T., Ahmed, F., Ahmad, A., Abbas, S., and Mahdi, F. (2014). The
role of vitamin e in human health and some diseases. Sultan Qaboos Univ. Med.
J. 14 (2), e157–e165.
Rodriguez-Cuenca, S., Cocheme, H. M., Logan, A., Abakumova, I., Prime, T. A.,
Rose, C., et al. (2010). Consequences of long-term oral administration of the
mitochondria-targeted antioxidant MitoQ to wild-type mice. Free Radic. Biol.
Med. 48 (1), 161–172. doi: 10.1016/j.freeradbiomed.2009.10.039
Sakai, S., Sugawara, T., Matsubara, K., and Hirata, T. (2009). Inhibitory effect of
carotenoids on the degranulation of mast cells via suppression of antigen-
induced aggregation of high affinity IgE receptors. J. Biol. Chem. 284 (41),
28172–28179. doi: 10.1074/jbc.M109.001099
Samuni, Y., Cook, J. A., Choudhuri, R., Degraff, W., Sowers, A. L., Krishna, M. C., et al.
(2010). Inhibition of adipogenesis by Tempol in 3T3-L1 cells. Free Radic. Biol. Med.
49 (4), 667–673. doi: 10.1016/j.freeradbiomed.2010.05.028
Samuni, Y., Goldstein, S., Dean, O. M., and Berk, M. (2013). The chemistry and
biological activities of N-acetylcysteine. Biochim. Biophys. Acta 1830 (8), 4117–
4129. doi: 10.1016/j.bbagen.2013.04.016
Schett, G., Zwerina, J., and Firestein, G. (2008). The p38 mitogen-activated protein
kinase (MAPK) pathway in rheumatoid arthritis. Ann. Rheum. Dis. 67 (7),
909–916. doi: 10.1136/ard.2007.074278
Schmitt, B., Vicenzi, M., Garrel, C., and Denis, F. M. (2015). Effects of N-
acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH
on oxidative stress markers: A comparative crossover study. Redox Biol. 6, 198–
205. doi: 10.1016/j.redox.2015.07.012
Schugar, R. C., Shih, D. M., Warrier, M., Helsley, R. N., Burrows, A., Ferguson, D.,
et al. (2017). The TMAO-Producing Enzyme Flavin-Containing
Monooxygenase 3 Regulates Obesity and the Beiging of White Adipose
Tissue. Cell Rep. 19 (12), 2451–2461. doi: 10.1016/j.celrep.2017.05.077
Schwarz, E. J., Reginato, M. J., Shao, D., Krakow, S. L., and Lazar, M. A. (1997).
Retinoic acid blocks adipogenesis by inhibiting C/EBPbeta-mediated
transcription. Mol. Cell Biol. 17 (3), 1552–1561. doi: 10.1128/MCB.17.3.1552
Seddon, M., Looi, Y. H., and Shah, A. M. (2007). Oxidative stress and redox
signalling in cardiac hypertrophy and heart failure. Heart 93 (8), 903–907. doi:
10.1136/hrt.2005.068270
Shen, F. C., Weng, S. W., Tsao, C. F., Lin, H. Y., Chang, C. S., Lin, C. Y., et al.
(2018). Early intervention of N-acetylcysteine better improves insulin
resistance in diet-induced obesity mice. Free Radic. Res. 52 (11-12), 1296–
1310. doi: 10.1080/10715762.2018.1447670
Siersbaek, R., Nielsen, R., and Mandrup, S. (2010). PPARgamma in adipocyte
differentiation and metabolism–novel insights from genome-wide studies.
FEBS Lett. 584 (15), 3242–3249. doi: 10.1016/j.febslet.2010.06.010
Singh, S., and Aggarwal, B. B. (1995). Activation of transcription factor NF-kappa
B is suppressed by curcumin (diferuloylmethane) [corrected]. J. Biol. Chem.
270 (42), 24995–25000. doi: 10.1074/jbc.270.42.24995
Sirico, F., Bianco, A., D'Alicandro, G., Castaldo, C., Montagnani, S., Spera, R., et al.
(2018). Effects of Physical Exercise on Adiponectin, Leptin, and Inflammatory
Markers in Childhood Obesity: Systematic Review and Meta-Analysis. Child
Obes. 14 (4), 207–217. doi: 10.1089/chi.2017.0269
Smith, B. K., Marcinko, K., Desjardins, E. M., Lally, J. S., Ford, R. J., and Steinberg,
G. R. (2016). Treatment of nonalcoholic fatty liver disease: role of AMPK. Am.
J. Physiol. Endocrinol. Metab. 311 (4), E730–E740. doi: 10.1152/ajpendo.
00225.2016
Soderberg, S., Ahren, B., Jansson, J. H., Johnson, O., Hallmans, G., Asplund, K.,
et al. (1999). Leptin is associated with increased risk of myocardial infarction. J.
Intern Med. 246 (4), 409–418. doi: 10.1046/j.1365-2796.1999.00571.x
Sodhi, K., Maxwell, K., Yan, Y., Liu, J., Chaudhry, M. A., Getty, M., et al. (2015).
pNaKtide inhibits Na/K-ATPase reactive oxygen species amplification and
attenuates adipogenesis. Sci. Adv. 1 (9), e1500781.
Sodhi, K., Puri, N., Favero, G., Stevens, S., Meadows, C., Abraham, N. G., et al.
(2015). Fructose Mediated Non-Alcoholic Fatty Liver Is Attenuated by HO-1-
SIRT1Module in Murine Hepatocytes andMice Fed a High Fructose Diet. PloS
One 10 (6), e0128648. doi: 10.1371/journal.pone.0128648
Sorrenti, V., Randazzo, C. L., Caggia, C., Ballistreri, G., Romeo, F. V., Fabroni, S., et al.
(2019). Beneficial Effects of Pomegranate Peel Extract and Probiotics on Pre-
adipocyte Differentiation. Front. Microbiol. 10:660. doi: 10.3389/fmicb.2019.00660
Sparkenbaugh, E. M., Chantrathammachart, P., Wang, S., Jonas, W., Kirchhofer,
D., Gailani, D., et al. (2015). Excess of heme induces tissue factor-dependent
activation of coagulation in mice. Haematologica 100 (3), 308–314. doi:
10.3324/haematol.2014.114728
Springer, M., and Moco, S. (2019). Resveratrol and Its Human Metabolites-Effects
on Metabolic Health and Obesity. Nutrients 11 (1). doi: 10.3390/nu11010143
Srikanthan, K., Feyh, A., Visweshwar, H., Shapiro, J.II, and Sodhi, K. (2016).
Systematic Review of Metabolic Syndrome Biomarkers: A Panel for Early
Detection, Management, and Risk Stratification in the West Virginian
Population. Int. J. Med. Sci. 13 (1), 25–38. doi: 10.7150/ijms.13800
Stolarczyk, E. (2017). Adipose tissue inflammation in obesity: a metabolic or
immune response? Curr. Opin. Pharmacol. 37, 35–40. doi: 10.1016/
j.coph.2017.08.006
Straub, L. G., Efthymiou, V., Grandl, G., Balaz, M., Challa, T. D., Truscello, L., et al.
(2019). Antioxidants protect against diabetes by improving glucose
homeostasis in mouse models of inducible insulin resistance and obesity.
Diabetologia 62 (11), 2094–2105. doi: 10.1007/s00125-019-4937-7
Sun, K., Kusminski, C. M., and Scherer, P. E. (2011). Adipose tissue remodeling
and obesity. J. Clin. Invest. 121 (6), 2094–2101. doi: 10.1172/JCI45887
Sun, K., et al. (2013). Fibrosis and adipose tissue dysfunction. Cell Metab. 18 (4),
470–477. doi: 10.1016/j.cmet.2013.06.016
Sun, J., Song, P., Wang, Y., and Chen, Y. (2019). Clinical efficacy of acetylcysteine
combined with tetrandrine tablets in the treatment of silicosis and the effect on serum
IL-6 and TNF-alpha. Exp. Ther. Med. 18 (5), 3383–3388. doi: 10.3892/etm.2019.7966
Takamiya, R., Murakami, M., Kajimura, M., Goda, N., Makino, N., Takamiya, Y.,
et al. (2002). Stabilization of mast cells by heme oxygenase-1: an anti-
inflammatory role. Am. J. Physiol. Heart Circ. Physiol. 283 (3), H861–H870.
doi: 10.1152/ajpheart.00740.2001
Talasaz, A. H., Khalili, H., Jenab, Y., Salarifar, M., Broumand, M. A., and Darabi, F.
(2013). N-Acetylcysteine effects on transforming growth factor-beta and tumor
necrosis factor-alpha serum levels as pro-fibrotic and inflammatory
biomarkers in patients following ST-segment elevation myocardial
infarction. Drugs R. D. 13 (3), 199–205. doi: 10.1007/s40268-013-0025-5
Thalhamer, T., McGrath, M. A., and Harnett, M. M. (2008). MAPKs and their
relevance to arthritis and inflammation. Rheumatol. (Oxford) 47 (4), 409–414.
Thompson, W. G., Cook, D. A., Clark, M. M., Bardia, A., and Levine, J. A. (2007).
Treatment of obesity.Mayo Clin. Proc. 82 (1), 93–101. quiz 101-2. doi: 10.1016/
S0025-6196(11)60971-3
Thong-Ngam, D., Samuhasaneeto, S., Kulaputana, O., and Klaikeaw, N. (2007). N-
acetylcysteine attenuates oxidative stress and liver pathology in rats with non-
alcoholic steatohepatitis. World J. Gastroenterol. 13 (38), 5127–5132. doi:
10.3748/wjg.v13.i38.5127
Tran, K., and Chan, A. C. (1990). R,R,R-alpha-tocopherol potentiates prostacyclin
release in human endothelial cells. Evidence for structural specificity of the
tocopherol molecule. Biochim. Biophys. Acta 1043 (2), 189–197. doi: 10.1016/
0005-2760(90)90295-9
Unal, R., Yao-Borengasser, A., Varma, V., Rasouli, N., Labbate, C., Kern, P. A.,
et al. (2010). Matrix metalloproteinase-9 is increased in obese subjects and
decreases in response to pioglitazone. J. Clin. Endocrinol. Metab. 95 (6), 2993–
3001. doi: 10.1210/jc.2009-2623
Upston, J. M., Kritharides, L., and Stocker, R. (2003). The role of vitamin E in
atherosclerosis.Prog. Lipid Res. 42 (5), 405–422. doi: 10.1016/S0163-7827(03)00024-9
von Lintig, J. (2012). Provitamin A metabolism and functions in mammalian
biology. Am. J. Clin. Nutr. 96 (5), 1234S–1244S. doi: 10.3945/ajcn.112.034629
Wagner, G., Lindroos-Christensen, J., Einwallner, E., Husa, J., Zapf, T. C., Lipp, K.,
et al. (2017). HO-1 inhibits preadipocyte proliferation and differentiation at the
onset of obesity via ROS dependent activation of Akt2. Sci. Rep. 7, 40881. doi:
10.1038/srep40881
Wallace, A. M., McMahon, A. D., Packard, C. J., Kelly, A., Shepherd, J., Gaw, A.,
et al. (2001). Plasma leptin and the risk of cardiovascular disease in the west of
Scotland coronary prevention study (WOSCOPS). Circulation 104 (25), 3052–
3056. doi: 10.1161/hc5001.101061
Wallert, M., Schmolz, L., Galli, F., Birringer, M., and Lorkowski, S. (2014).
Regulatory metabolites of vitamin E and their putative relevance for
atherogenesis. Redox Biol. 2, 495–503. doi: 10.1016/j.redox.2014.02.002
Tun et al. Antioxidants Ameliorate Obesity Phenotype
Frontiers in Pharmacology | www.frontiersin.org August 2020 | Volume 11 | Article 123419
Wang, W., Connor, S. L., Johnson, E. J., Klein, M. L., Hughes, S., and Connor, W. E.
(2007). Effect of dietary lutein and zeaxanthin on plasma carotenoids and their
transport in lipoproteins in age-related macular degeneration. Am. J. Clin. Nutr.
85 (3), 762–769. doi: 10.1093/ajcn/85.3.762
Wang, X. M., Kim, H. P., Nakahira, K., Ryter, S. W., and Choi, A. M. (2009). The
heme oxygenase-1/carbon monoxide pathway suppresses TLR4 signaling by
regulating the interaction of TLR4 with caveolin-1. J. Immunol. 182 (6), 3809–
3818. doi: 10.4049/jimmunol.0712437
Wang, S. L., Li, Y., Wen, Y., Chen, Y. F., Na, L. X., Li, S. T., et al. (2009). Curcumin,
a potential inhibitor of up-regulation of TNF-alpha and IL-6 induced by
palmitate in 3T3-L1 adipocytes through NF-kappaB and JNK pathway.
BioMed. Environ. Sci. 22 (1), 32–39. doi: 10.1016/S0895-3988(09)60019-2
Wang, X., Liu, J. Z., Hu, J. X., Wu, H., Li, Y. L., Chen, H. L., et al. (2011). ROS-
activated p38 MAPK/ERK-Akt cascade plays a central role in palmitic acid-
stimulated hepatocyte proliferation. Free Radic. Biol. Med. 51 (2), 539–551. doi:
10.1016/j.freeradbiomed.2011.04.019
Wang, C. H., Wu, S. B., Wu, Y. T., and Wei, Y. H. (2013). Oxidative stress response
elicited by mitochondrial dysfunction: implication in the pathophysiology of aging.
Exp. Biol. Med. (Maywood) 238 (5), 450–460. doi: 10.1177/1535370213493069
Wang, B., Aw, T. Y., and Stokes, K. Y. (2016). The protection conferred against
ischemia-reperfusion injury in the diabetic brain by N-acetylcysteine is
associated with decreased dicarbonyl stress. Free Radic. Biol. Med. 96, 89–98.
doi: 10.1016/j.freeradbiomed.2016.03.038
Wegiel, B., and Otterbein, L. E. (2012). Go green: the anti-inflammatory effects of
biliverdin reductase. Front. Pharmacol. 3, 47. doi: 10.3389/fphar.2012.00047
Wensveen, F. M., Valentic, S., Sestan, M., Turk Wensveen, T., and Polic, B. (2015).
The “Big Bang” in obese fat: Events initiating obesity-induced adipose tissue
inflammation. Eur. J. Immunol. 45 (9), 2446–2456. doi: 10.1002/eji.201545502
Widjaja, S. S., Syahputra, M. O. K., and Ginting, A. (2019). Hypercoagulable State
and Glycemic Control in Diabetic Patients with Malignancy. Open Access
Maced J. Med. Sci. 7 (23), 4066–4068. doi: 10.3889/oamjms.2019.860
Wiseman, S. A., Van den Boom, M. A., De Fouw, N. J., Wassink, M. G., Op den
Kamp, J. A., and Tijburg, L. B. (1995). Comparison of the effects of dietary
vitamin E on in vivo and in vitro parameters of lipid peroxidation in the rabbit.
Free Radic. Biol. Med. 19 (5), 617–626. doi: 10.1016/0891-5849(95)00078-C
Wong, S. K., Chin, K. Y., Suhaimi, F. H., Ahmad, F., and Ima-Nirwana, S. (2017).
Vitamin E As a Potential Interventional Treatment for Metabolic Syndrome:
Evidence from Animal and Human Studies. Front. Pharmacol. 8, 444. doi:
10.3389/fphar.2017.00444
Wood Dos Santos, T., Cristina Pereira, Q., Teixeira, L., Gambero, A. J. A. V., and
Lima Ribeiro, M. (2018). Effects of Polyphenols on Thermogenesis and
Mitochondrial Biogenesis. Int. J. Mol. Sci. 19 (9). doi: 10.3390/ijms19092757
Wood, Z. A., Schroder, E., Robin Harris, J., and Poole, L. B. (2003). Structure,
mechanism and regulation of peroxiredoxins. Trends Biochem. Sci. 28 (1), 32–
40. doi: 10.1016/S0968-0004(02)00003-8
Wu, J. H., Ward, N. C., Indrawan, A. P., Almeida, C. A., Hodgson, J. M., Proudfoot,
J. M., et al. (2007). Effects of alpha-tocopherol and mixed tocopherol
supplementation on markers of oxidative stress and inflammation in type 2
diabetes. Clin. Chem. 53 (3), 511–519. doi: 10.1373/clinchem.2006.076992
Wu, B., Wu, Y., and Tang, W. (2019). Heme Catabolic Pathway in Inflammation
and Immune Disorders. Front. Pharmacol. 10:825. doi: 10.3389/
fphar.2019.00825
Yamada, S., and Guo, X. (2018). Peroxiredoxin 4 (PRDX4): Its critical in vivo roles
in animal models of metabolic syndrome ranging from atherosclerosis to
nonalcoholic fatty liver disease. Pathol. Int. 68 (2), 91–101. doi: 10.1111/
pin.12634
Zaragoza, A., Diez-Fernandez, C., Alvarez, A. M., Andres, D., and Cascales, M.
(2000). Effect of N-acetylcysteine and deferoxamine on endogenous
antioxidant defense system gene expression in a rat hepatocyte model of
cocaine cytotoxicity. Biochim. Biophys. Acta 1496 (2-3), 183–195. doi: 10.1016/
S0167-4889(00)00036-7
Zelko, I. N., Mariani, T. J., and Folz, R. J. (2002). Superoxide dismutase multigene
family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-
SOD (SOD3) gene structures, evolution, and expression. Free Radic. Biol. Med.
33 (3), 337–349. doi: 10.1016/S0891-5849(02)00905-X
Zhang, Q., Yuan, H., Zhang, C., Guan, Y., Wu, Y., Ling, F., et al. (2018).
Epigallocatechin gallate improves insulin resistance in HepG2 cells through
alleviating inflammation and lipotoxicity. Diabetes Res. Clin. Pract. 142, 363–
373. doi: 10.1016/j.diabres.2018.06.017
Zicha, J., Dobesova, Z., and Kunes, J. (2006). Antihypertensive mechanisms of
chronic captopril or N-acetylcysteine treatment in L-NAME hypertensive rats.
Hypertens. Res. 29 (12), 1021–1027. doi: 10.1291/hypres.29.1021
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Tun, Spainhower, Cottrill, Lakhani, Pillai, Dilip, Chaudhry,
Shapiro and Sodhi. This is an open-access article distributed under the terms of the
Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal is
cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Tun et al. Antioxidants Ameliorate Obesity Phenotype
Frontiers in Pharmacology | www.frontiersin.org August 2020 | Volume 11 | Article 123420
